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Abstract
The efficacy of radiotherapy is dependent on its precision and accuracy. Increasingly
conformal, modulated radiation fields can be reproducibly delivered to small, complex
volumes within the human body. However, treatment is not without uncertainty. This
thesis focuses on limitations in radiotherapy accuracy due to uncertainty in delineation of
the volume requiring treatment.
Delineation of the target volume occurs on computed tomography (CT) imaging (with
or without aid from other imaging) and is manually drawn by the radiation oncologist.
The inability to visualise individual cancer cells in situ with current imaging means that
an oncologist’s contour is highly subjective. This potential inconsistency in contours and
hence, treatment plans for the same patient can obscure results of trial data, as well as
result in suboptimal plans for the individual patient.
This thesis investigated the importance of inter-observer variation in radiotherapy. The
variability in high risk clinical target volume (CTVHR) delineation for high dose rate
(HDR) cervical cancer brachytherapy was quantified and the dosimetric consequences of
this variation was assessed. A wide range in variability when considering each individual
contour was observed, with an average mean absolute surface distance (MASD) of (7.13
± 6.37) mm and an average dice similarity coefficient (DSC) of (0.63 ± 0.15). The
maximum dimensions of the CTVHR contour demonstrated 0.75 cm - 1.82 cm variation
and the mean volume varied by 28.5 cm3. The average dosimetric uncertainty across a
treatment course that arises as a result of this variability was shown to be 2.9 Gy - 3.4 Gy
iv
vEQD210 for an Australian dataset and 1.9 Gy - 2.8 Gy EQD210 for a gold standard
European dataset. The European data demonstrated a correlation between lateral
dimensions and volume with dose to 98% of the volume (D98). This was validated with
the independent Australian dataset.
In an attempt to minimise inter-observer variation, an atlas-based auto-segmentation
method was proposed and investigated for whole breast external beam radiotherapy. The
utilisation of this approach in the radiotherapy treatment planning process would
minimise inter-observer variation arising from manual contouring. The auto-segmented
contours were accurate, demonstrating good similarity when compared to the gold
standard contour (DSC > 0.7 and MASD < 1 cm).
Finally, it is acknowledged that it is unlikely that inter-observer variation will be entirely
eliminated as long as subjective interpretation of images remains a requirement in
radiotherapy. Hence, a delineation uncertainty margin was proposed and investigated.
The coordinate system most appropriate for this margin (as assessed on whole breast
radiotherapy volumes) was spherical coordinates, however cardinal expansions were also
found to be appropriate for small breast volumes. Delineation uncertainty margin
magnitudes ranged from 3.2 mm - 14.5 mm for spherically defined margins, 3.0 mm -
17.6 mm for polar margins and 1.6 mm - 15.8 mm for cartesian defined margins.
Acceptable clinical target volume (CTV) observer coverage was determined with > 95%
of observer contours included in the delineation margin for all coordinate systems. The
volume expanded by the margin was assessed to ensure that unnecessary healthy tissue
was not included and malignant tissue was not missed. The delineation uncertainty
margin produced volumes within accepted tolerances for the majority of cases.
In order to improve patient outcomes, sources of uncertainty must be minimised. Inter-
observer variation is one of the largest sources of uncertainty in the radiotherapy process.
This thesis presents a series of investigations that attempt to understand the impact this
vi
uncertainty has on treatment, minimise the human intervention in the process such that
consistency might be improved and manage its presence for the benefit of improved cancer
patient treatment outcomes.
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Chapter 1
Introduction
The efficacy of radiotherapy is dependent on its precision and accuracy. Increasingly
conformal, modulated radiation fields can be reproducibly delivered to small, complex
volumes within the human body. The advancements in technology that have enabled
this precision have resulted in improvements in patient outcomes. In order to continue
to provide optimal treatment for patients, remaining uncertainties must be minimised.
One of the largest sources of uncertainty affecting radiotherapy accuracy is variability in
delineation of the volume requiring treatment.
Delineation of the target volume occurs on computed tomography (CT) imaging (with or
without aid from other imaging) and is manually drawn by the radiation oncologist.
Herein lies the problem. By defining a binary volume (malignant cells inside, healthy
cells outside), differences in observer decisions are emphasised, as opposed to
identifying a region of varying probability of malignant cells. The issue is complicated
by the inability to visualise individual cancer cells in situ with current imaging. A
radiotherapy plan optimised to an oncologist’s contour will differ to that of another
oncologist. This potential inconsistency in treatment plans for the same patient can
obscure results of trial data, as well as result in suboptimal plans for the individual
patient. Further complicating the issue is the lack of knowledge of a ground truth. Not
only will different oncologists produce different contours, and hence treatment plans, we
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do not, and cannot know with current technologies, which oncologist is correct at a
cellular level without retrospective pathological studies.
Volumes are an essential component of the treatment planning process, mostly due to the
facilitation of dose-volume histograms that are used in dose reporting. However, the
aforementioned issues justify questioning whether they are an optimal tool for planning
purposes. Perhaps in the future radiotherapy treatments will dosimetrically vary with the
probability of microscopic cancer, as opposed to relying on dose gradients to encompass
any cells that may have been missed in the original target volume. Nevertheless, the
current process is such that a hard line is drawn and hence, attempts to understand,
minimise and manage this uncertainty in treatment planning need to be
investigated.
This thesis investigates the variation in observers when delineating a target volume. It
investigates the impact on dosimetric outcomes and methods to minimise the human
intervention in the process such that consistency might be improved; and defines and
analyses an uncertainty margin to best manage this uncertainty.
1.1 Project Aims
This section outlines the scope of this project by stating the project aims with associated
research questions and the thesis chapters that address each. The three main aims explored
in this thesis centered on delineation uncertainty are outlined below.
Aim 1. Understand the impact of delineation uncertainty on radiotherapy efficacy
Research questions:
What is the magnitude of inter-observer variation for high dose rate
cervical cancer brachytherapy in the Australian context?
How does inter-observer variation affect the dosimetric parameters
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obtained during the radiotherapy treatment planning process?
Do common metrics used to assess contouring consistency correlate
with dosimetric outcomes?
Content Overview:
Chapter 3 quantifies the variability in high-risk clinical target volumes
(CTVHR) delineation for high dose rate (HDR) cervical cancer
brachytherapy and assesses the dosimetric consequences of this variation
on a gold standard target volume. Chapter 4 investigates the dose planning
variation that arises from inter-observer variation when individual plans
are optimised to individual contours of a Groupe Europe´en de
Curiethe´rapie and the European Society for Radiotherapy and Oncology
(GEC-ESTRO) inter-observer variation dataset. Chapter 5 validates the
findings of Chapter 4 in the Australian context.
Aim 2. Minimise delineation uncertainty by automating the contouring process
Research questions:
Can an accurate automatic segmentation method be developed to
reduce the magnitude of delineation uncertainty?
Content Overview:
Chapter 6 investigates an atlas-based auto-segmentation method that
incorporates inter-observer variation. It is assessed on a whole breast
external beam radiotherapy dataset.
Aim 3. Manage delineation uncertainty using an uncertainty margin
Research questions:
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What is the best coordinate system to define a delineation uncertainty
margin for whole breast external beam radiotherapy?
Can inter-observer variation be accounted for appropriately with an
uncertainty margin?
Content Overview:
Chapter 7 presents an investigation into the most appropriate coordinate
system to define a delineation uncertainty margin for whole breast
radiotherapy. Chapter 8 expands on these findings to define and assess a
margin for this cohort.
Chapter 2
Literature Review
2.1 Radiotherapy
Globally, cancer incidence and mortality is growing, with an estimated 18.1 million new
cases and 9.6 million deaths in 2018 [1]. The 2018 Global Cancer Statistics report
identifies the cumulative risk of developing cancer before the age of 75 as 21.4% and the
risk of death as 17.7% [1]. Australia and New Zealand have the highest overall incidence
rates globally with a cumulative risk in males of 49.1% and 33.3% in females [1]. The
cumulative risk of death is comparatively low (10.8% in males and 8.1%) indicating the
tremendous ongoing treatment burden for the Australian health care system [1].
The most common modalities available to treat cancer are radiotherapy, chemotherapy
and surgery. The radiotherapy utilisation rate in Australia is 48.3% [2]. This means that
approximately half of cancer patients would benefit from radiotherapy treatment at some
point in their treatment journey, either in an adjuvant setting, or as the primary treatment
modality. Radiotherapy utilises ionising radiation such as photons, electrons, protons or
heavy ions, that damage and can destroy cancer cells by depositing energy within their
vicinity. This energy deposition also damages healthy cells in the area being irradiated.
However, healthy cells repair faster than cancer cells when exposed to radiation. By
delivering radiation in small doses with short breaks in between, the differences in repair
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Figure 2.1: General radiotherapy process [3].
time can be fortuitously exploited. The cumulative damage to the cancer cells relative to
the healthy cells increases with each fraction, forming the basis of therapy.
Radiotherapy is a multi-step, multi-discipline process. The general radiotherapy process
is outlined in Figure 2.1.
Diagnosis is achieved via a combination of diagnostic imaging, biopsies, pathology and
review of symptoms. Once a cancer diagnosis is made, the patient is referred to an
oncologist who, as part of a team of specialists, will decide on the treatment course. If
radiotherapy is considered, a radiation oncologist is referred to. One of the first things a
radiation oncologist does is review existing diagnostic images and request further
imaging for therapeutic purposes.
Imaging is an important part of the treatment chain as it facilitates tumour localisation
and provides the tissue information required to calculate dose. CT is required in most
treatment methods, however positron emission tomography (PET), magnetic resonance
imaging (MRI) and ultrasound (US) provide beneficial supplementary information and
are recommended in many instances.
Volume delineation is performed by the radiation oncologist and involves identifying the
area which is intended to be treated on the CT dataset (or otherwise as appropriate). This
often requires a volumetric delineation of the region. Target and organ at risk (OAR)
delineation is essential for dose prescription, recording and reporting. International
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Figure 2.2: Schematic illustration of the different radiotherapy volumes. The clinical
target volume (CTV) encompasses the gross tumour volume (GTV) and microscopic
spread of the cancer. The planning target volume (PTV) is an extension of the CTV in
the cardinal directions to account for uncertainties.
Commission on Radiation Units and Measurements (ICRU) Reports 50 and 62 identify
specific regions required for treatment with varying concentrations of malignant cells [4,
5]. Figure 2.2 is a schematic illustration of the different volumes. The gross tumour
volume (GTV) should include the malignant growth as is visible or palpable. The
clinical target volume (CTV) includes the GTV and any microscopic spread of the
malignant disease. The planning target volume (PTV) is an extension of the CTV to
account for all treatment uncertainties. The OARs are also delineated, to which dose
should be minimised.
The radiotherapy planning stage involves the development and application of a set of
instructions that will be sent to the treatment machine to achieve a desired outcome. The
amount of dose that should be delivered to the CTV and the dose constraints to OARs
is specified. Treatment parameters such as fluence, beam energy, angle and aperture are
optimised to achieve these goals.
Once the treatment is planned, the patient is positioned on the treatment couch in a
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specific, reproducible way. Immobilisation equipment and techniques are used to
minimise uncertainties. Immobilisation is essential in ensuring the planned treatment is
delivered as intended.
Radiation treatment modalities fall into two broad categories: external beam radiotherapy
(EBRT) and brachytherapy. EBRT is delivered via a linear accelerator which produces a
beam of radiation that can be centred on the treatment target. A combination of different
beam angles and shapes can be used to conform dose to the target volume within the
patient in three dimensions. Brachytherapy utilises radioactive sources by placing them
in close proximity of the treatment volume. For treatment sites other than the skin, this is
achieved via interstitial needles or intra-cavitary techniques. Sources can be high or low
dose rate, requiring short treatment times or permanent insertion respectively.
2.2 Types of Uncertainties in Radiotherapy
Every step of the radiotherapy process has the potential to introduce uncertainty into the
accuracy of the delivered dose. An uncertainty in radiotherapy is defined as any deviation
from the planned irradiation geometry during the radiotherapy process. The introduction
of uncertainty may result in an under-dosing of the target volume, and an over-dose of
the organs at risk [3]. If the uncertainty is large enough or target volumes small enough,
geometric miss may occur.
Uncertainties can have systematic and/or random components. Systematic uncertainties
are consistent, repeatable uncertainties that occur throughout a fractionated treatment
course. The combined standard deviation (SD) of all systematic uncertainties is
represented by ’Σ’ [6]. Random uncertainties are unpredictable fraction-to-fraction
variations. The combined SD of all random errors are represented by ’σ ’ [6].
Sources of uncertainties in radiotherapy can be broadly classified into set up uncertainties,
motion uncertainties and delineation uncertainties. Motion uncertainties encompass any
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movement during treatment that deviates from the patient anatomy at the time of treatment
planning imaging. This encompasses motion of the patient after they have been set up for
treatment (e.g. moving their head), as well as motion during the treatment delivery (e.g.
lung motion due to breathing).
Set up uncertainties occur when there is a discrepancy between intended and actual
treatment position at the time of treatment set up. This includes a shift or rotation of the
patient in a particular direction, an incorrect field shape or size and incorrect isocentre
positioning [7]. Set up uncertainties can be inter-fraction, meaning the uncertainty can
vary between fractions; or intra-fraction meaning during fractions, as exampled by a
couch positional difference between fields. Anatomical changes such as systematic
weight loss, or variable bladder volume can be classified as set up uncertainty.
Delineation uncertainties represent the uncertainty in defining the ’true’ treatment
volume on the planning images. This uncertainty is difficult to quantify as the true
treatment volume can only be determined with biopsies and pathology since individual
microscopic cancer cells aren’t visible on current therapeutic imaging. Delineation
uncertainty results in intra-observer variation and inter-observer variation. Intra-observer
variation occurs when a single observer produces different contours when delineating
multiple times (presented with the same information). Inter-observer variation is the
variation in contours produced by different observers. Inter-observer variation is the
focus of this thesis. The origin of this variation lies in the individual, human
interpretation of the data presented. In practice, surrogates such as CT images are used
for delineation however this enables differences in image interpretation due to reasons
including observer experience, imaging modality, windowing and levelling and room
lighting.
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2.3 Managing Uncertainties in Radiotherapy
It is unrealistic to expect that all uncertainties can be eliminated with current
radiotherapy technology, however the presence of uncertainty and its impact can be
minimised in a number of ways. Patient immobilisation equipment such as breast
boards, head and neck masks and vacuum bags can serve to increase positional accuracy
and constancy throughout treatment. Image-guided radiotherapy includes the use of
imaging prior, during and after treatment to ensure the anatomy at the time of treatment
matches the anatomy that the treatment plan was generated on. Conventional
on-treatment imaging utilises a kilovoltage source and detector system mounted to the
linear accelerator, enabling bony anatomy and some soft tissue to be visualised in a
planar or volumetric acquisition. This imaging is primarily focused on maximising set
up accuracy and in some cases motion management. Pre- and post- treatment imaging
can be more sophisticated due to the increased time available for acquisition and
scheduling flexibility. This can include PET, MRI or high quality CT imaging for target
localisation improvements or for characterisation of the tumours range of motion.
Finally, quality assurance programs are put in place to ensure that all equipment in the
radiotherapy chain behaves in an accurate and reproducible way. For example, the impact
of superior on-treatment imaging can be negated if the couch shifts as determined by the
software, aren’t physically achievable.
The implementation of these methods to account for radiotherapy treatment uncertainties
has served to reduce their magnitude. To account for residual set-up and organ positional
uncertainties, ICRU reports 50 and 62 state that a margin should be generated around the
CTV [4, 5]. To determine a margin, the magnitude of the combined uncertainty impacting
the dose distribution must be determined. A common method utilises the central limit
theorem to estimate the combined contribution of each source of error at the multiple
time points that they may manifest [6]. The theorem assumes that the sum of many
distributions with arbitrary shape will approach a normal Gaussian distribution. As such,
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the SD from the mean of the measured errors is used to represent a population of errors
[8].
ICRU Report 62 suggests that the root sum squares of the SD in each source of uncertainty
should be used as a means of combining them (Equation 2.1) [5]. Linear additions of each
source of uncertainty are not recommended.
σtotal =
√
σ2setup+σ2motion (2.1)
There are no recommendations in the ICRU reports on how to combine systematic and
random components to achieve a singular SD for each source of uncertainty. Systematic
uncertainties are known to affect the dose distribution quantitatively more than random
uncertainties [9, 10]. Furthermore, systematic uncertainties are shown to shift the
distribution as opposed to random uncertainties which blur the dose distribution [11].
This inherent difference between the two types implies that independent margins for
systematic and random uncertainties should be used, and that a weighted sum should be
used when combining these margins.
Several weighted combinations of systematic and random uncertainties have been
published in regards to defining an uncertainty margin. These algorithms will be referred
to as ’margin recipes’. Recipes accounting for just random uncertainties, as well as
empirical recipes accounting for the microscopic expansion of the GTV to the CTV have
been published. Table 2.1 presents the main margin recipes that exist in current
literature.
There are two main derivations of the CTV-PTV margin in the literature [9, 14].
The margin method proposed by van Herk et al assessed the impact of uncertainties on the
delivered dose and used this to determine the smallest acceptable margin around the CTV
to account for it [14]. The margin aimed to ensure that 90% of the population received
a minimum dose to the CTV of 95% the nominal dose. The systematic and random
CHAPTER 2. LITERATURE REVIEW 12
Table 2.1: Margin recipes to expand radiotherapy volumes to account for uncertainties
(CTV to PTV). Adapted and updated from Table 2 in van Herk et al [6].
Authors Year Recipe
Bel et al [12] 1996 0.7σ
Antolak and Rosen [13] 1999 1.65σ
Stroom et al [9] 1999 2Σ+0.7σ
van Herk et al [14] 2000 2.5Σ+0.7σ
2.5Σ+1.64(σ −σp)
McKenzie et al [15] 2000 2.5Σ+β (σ −σp)
Parker et al [16] 2002 Σ+
√
(σ2+Σ2)
van Herk et al [10] 2002 2.5Σ+0.7σ −3mm√
(2.7Σ)2+(1.6σ)2−2.8mm
Topolnjak et al [17] 2008 2.5Σ+0.3σ
McKenzie et al [18] 2002 1.3Σ
1.3Σ+0.5σ (for blurring)
1.3Σ−0.5σ
Stroom et al [8] 2014 2.1Σ+0.8σ for clinical plans
2.5Σ+0.9σ ideal scenario
components of uncertainties were treated separately.
The change in dose distribution for an individual patient was determined by first
convolving the planned dose distribution with the random errors to estimate the
cumulative blurred dose distribution arising from multiple treatment fractions. The
blurred dose distribution was shifted by an amount and direction corresponding to a
given systematic error. This was repeated for all systematic errors to obtain the dose
distribution that would be delivered when accounting for all uncertainties.
Once the change in dose distribution due to uncertainties for a population of patients
was known, the margin could be determined. For the systematic component, an ellipsoid
of vector radius αΣ was used to describe the possible shifts of the CTV, where Σ is a
vector describing the systematic component of the uncertainties and α is the factor that
ensures 90% confidence that the ellipsoid encompasses the systematic uncertainties in
three dimensions.
After correcting the planned dose distribution for systematic uncertainties, the difference
between 95% isodose (for example) of the planned dose distribution and the 95% isodose
of the blurred dose distribution was the additional margin required to account for random
uncertainties. This could be expressed as βσ -βσρ where βσ is the distance between a
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reference 50% and the 95% isodose surface for the cumulative dose distribution, and the
βσρ is the same distance but for the planned dose distribution. σρ is the SD describing
the width of the penumbra. The 50% isodose surface was taken as a reference point as its
position is constant, even with blurring.
The margins for systematic uncertainties, and random uncertainties were linearly added.
The margin recipe that met the specified criteria of 95% dose to the CTV for 90% of the
population is seen in Equation 2.2.
2.5Σ+0.7σ (2.2)
Limitations with this derivation include the fact that idealised dose distributions and dose
conformation were assumed, the errors were assumed to have isotropic effects in all
directions, and no rotational errors and shape variations were considered.
A second type of margin derivation method, proposed by Stroom et al, utilises ’coverage
probabilities’ [9]. The CTV for a particular patient was converted into a 3D binary
image, with values of one inside the CTV and zero outside. The binary CTV was
convolved with the normal distribution of systematic uncertainties to obtain a coverage
probability matrix. This is the probability of each point to be covered by the CTV. The
2.5% iso-probability curve corresponding to the volume bounded by voxels having a
coverage probability of 2.5%, was taken as the expansion of the CTV for systematic
uncertainties (PTV1). To account for random uncertainties, a smaller expansion was
needed. PTV1 was convolved with the normal distribution of random uncertainties to
obtain the final coverage probability matrix. The 25% iso-probability volume was taken
to account for random deviations.
Based on the condition that on average, 99% of the CTV receives greater than 95% of the
planned dose, the margin recipe seen in Equation 2.3 was suggested.
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2Σ+0.7σ (2.3)
Limitations with this recipe lie in the fact that only set up errors were considered and all
errors were mutually independent and Gaussian in nature.
It is interesting to note that even with two completely different methods of defining a
margin recipe and with different, though admittedly similar criteria, Equation 2.3 and
Equation 2.2 are near identical, with just a small numerical difference between the Σ
scaling coefficient.
2.4 Inter-observer Variation - The Weak Link
Radiotherapy has undergone substantial technological advancement in the last 50 years
resulting in significant improvement in local control rates [19]. Treatments have
progressed from large, open fields with limited beam angles, to highly conformal
volumetric treatments [19]. Paramount to this technology and technique progression is
the requirement to correctly identify the region to be treated [3, 20]. The ability to
accurately deliver conformal treatments, often consisting of high doses in single or few
fractions, depends on delineation accuracy to ensure geometrical miss of the tumour and
over-irradiation of normal tissue is avoided.
The quality of radiotherapy is only as strong as its weakest link. A large scale clinical trial
showed that radiotherapy of head and neck cancer could have markedly inferior outcome
if treatment protocols were not adhered to [21]. Specifically, poor radiotherapy was found
to result in an approximate 20% decrease on 2-year overall survival for advanced head
and neck cancer. Target volume definition inaccuracies were identified as having the most
serious implications, exceeding the impact of dose distribution inadequacies and incorrect
dose prescriptions.
The largest factor contributing to uncertainty in delineation, is inter-observer variation [3].
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Inter-observer variation occurs due to the difficulty in identifying the true contour based
on imaging. For the specific case of the CTV, microscopic disease cannot be visualised
with current therapeutic imaging capabilities and spatial resolution limitations. Without
this knowledge of a true volume, the CTV is defined based on an individual clinician’s
judgement on what tissue may contain malignant cells at one particular time-point. The
factors influencing this judgment include observer experience and training [21–24], the
imaging modalities available [25–28], availability and adherence to contouring protocols
[21, 29] and patient/tumour specific factors [30, 31].
2.5 Quantifying Inter-Observer Variation
Metrics used to quantify delineation uncertainty are varied amongst the literature, with
no consensus between studies as to which metric(s) should be used [32–34]. Metrics to
describe a radiotherapy target delineation include volume, dimensions, shape and centre
of volume. Most studies utilise a combination of metrics due to the limitations in each
[34]. It appears that in different anatomical locations, some metrics may be more
appropriate than others [35, 36].
2.5.1 Volume
Volume is a metric that describes the amount of tissue encompassed by a delineation. It
is typically determined by identifying the number of voxels contained within the contour
and multiplying by the voxel size. However, different software may calculate volume
slightly differently. Volume comparison is excellent for providing a comparison of the
size of delineations, however it lacks spatial and shape information. Volume is the most
commonly reported metric in delineation studies [33, 34].
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2.5.2 Centre of Mass
The centre of mass (COM) is a single point identifying the centre of a delineation in
three dimensions. This metric gives an indication of the positional similarities between
delineations, but no shape or size information is obtained. COM is often reported in
delineation uncertainties studies, however it is rarely the only reported metric [34].
2.5.3 Dimensions
A delineation can be described by how much it extends in specific dimensions.
Delineation uncertainty amongst a cohort of delineations can be determined by
calculating the SD in extension along a specific axis. Dimensions can be determined by
defining a cuboid around the delineation such that the surfaces of the cuboid abut the
surfaces of the delineation [33]. The known dimensions of the cuboid therefore indicate
the dimensions of the delineation in those directions. Alternatively, a vector emanating
from the COM of the delineation can identify the dimensions of the shape by finding the
distance at which the vector intersects the delineation. Depending on the number of axes
reported, dimension metrics can describe the shape and size of a delineation.
Dimensions can sometimes be misleading if there are surface variations that occur
between the axes investigated.
2.5.4 Volume Overlap Metrics
Volume overlap metrics are measures of the overlap between two volumes. They attempt
to overcome the lack of spatial information in a volume metric, however in a relative
capacity only. Generally, a value of 1 represents 100% overlap of the two delineations
and a value of 0 indicates zero overlap. Volume overlap metrics commonly utilise the
union and/or intersection volumes of two delineations. Two of the most common metrics
in the literature are the Jaccard Index and the Dice Similarity Coefficient (DSC). The
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Jaccard Index is the ratio of the volume of overlap to the encompassing volume of two
delineations as seen in Equation 2.4.
JaccardIndex =
|V1∩V2|
|V1∪V2| (2.4)
The Jaccard index has been used extensively in the literature but is referred to by a number
of names including ’conformity index’ [37], ’concordance index’ (CI) [31] and ’ratio of
common to encompassing volume’ [25, 29, 38]. This lack of consistent terminology
adds to the difficulty in comparing delineation uncertainty studies. It was first proposed
as a tool for botanic comparisons and was termed the ’coefficient de communaute’ [39,
40].
The DSC was first proposed in an ecology journal (called the ’coincidence index’) as a
metric that quantifies the association between two groups independent of which group is
used as the base [41]. It is similar to the Jaccard index however places greater weight on
the intersecting volume of delineations.
DSC =
2|V1∩V2|
|V1|+ |V2| (2.5)
The above metrics can be used to characterise a cohort of delineations; however it is
most meaningful to compare each delineation to a reference delineation. This is
especially relevant for overlap metrics. The reference delineation should be a ground
truth delineation which ideally encompasses 100% of the malignant cells and 0% normal
tissue. However, in the absence of patient specific pathology slides, the absolute
accuracy of the target volume is unable to be determined. Therefore, the reference
delineation must be a best estimation for the ground truth. Methods to determine a
reference delineation include a mathematical estimate of the true contour [42] or
manually generated by an individual or panel of experts [33]. One study by Gao et al
utilised images from the Visible Human Project to use as a gold standard [43].
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2.6 Impact of Imaging on Inter-Observer Variation
CT images are the current standard of care for external beam radiotherapy due to the
provision of electron densities that are required for treatment planning. However, a
number of other auxiliary imaging modalities and techniques are often utilised to
improve visualisation of the regions of interest. Most commonly used in clinical
treatment planning workflow are MRI and PET. The use of contrast enhancing agents
can also improve the ability to visualise regions of interest. Image resolution has been
shown to impact inter-observer agreement, with high resolution images producing the
greatest agreement in delineations [44]. Each imaging modality and type has its own
advantages and disadvantages which can be exploited to improve delineation
uncertainty.
MRI has the advantage of improved soft tissue contrast compared to CT. Delineations
drawn on MRIs differ in size and shape than their equivalents on CT for prostate, brain,
bone metastases and breast cancers [38, 45–47]. However, despite improved tissue
contrast and the associated hypothesis that delineation uncertainty may be reduced, this
isn’t always the case. Breast contours defined on both MRI and on CT were shown to
have comparable delineation uncertainty [45, 47] and the combination of MRI to CT for
brain delineation did not reduce inter-observer variation [46]. Conversely, head and neck
and prostate cancer MRI contours had less inter-observer variation than CT [48, 49] and
delineations of bone metastases were most consistent on MRI [47]. The difference in
inter-observer variation reduction may be attributed to the fact that breast and brain
target volumes are already fairly well visualised on CT, especially with contrast agents,
therefore the improved soft tissue image quality of MRI is hypothesised to have a
negligible impact on the uncertainty in delineation. For head and neck tumours as well
as prostate where the boundaries are less obvious in CT, MRI enables better visualisation
and therefore better consistency in delineation. Weltens et al doesn’t discredit the use of
MRI for brain, despite no change in delineation uncertainty. The utilisation of both
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modalities in conjunction with each other enables an informed delineation decision,
especially since the ground truth is not known [46].
In most cases PET helps reduce inter-observer variation in lung when acquired in
conjunction with a CT (PET-CT) [25, 39, 50, 51]. This is due to the additional biological
information of metabolically active areas in PET images compared to conventional CT.
However, delineation uncertainty is still substantial for PET-CT lung delineations [25,
51, 52]. Additionally, one study found that the utilisation of PET-CT images for NSCLC
did not improve the concordance index of observer volumes, though the authors
acknowledge that the study was underpowered [53]. PET based tumour volumes have
been shown to be strongly affected by the choice of threshold level in the specific uptake
value [50]. For head and neck tumours, one study found no change in inter-observer
variation between PET-CT and CT defined contours [54].
The use of multi-modality imaging is identified as being the most appropriate approach
to target volume delineation [55]. Although multi-modality contouring may improve
delineation uncertainty, it has been shown that delineation uncertainty still persists. Even
when the structure being contoured is well visualised as in the Visible Human Projects
images, delineation uncertainty remains [43]. Bernier, Hall and Giaccia identified
molecular biology and genetics as being the next step in improving target definition and
radiotherapy quality in general [19].
2.7 Impact of Anatomical Location on Inter-Observer
Variation
Inter-observer variation is substantial in a number of anatomical sites including soft tissue
sarcoma, pituitary adenoma and brain tumours [20, 30, 34, 46, 56]. Some anatomical sites
are more conducive to inter-observer variation than others with high contrast tumours
more easily visualised than soft tissue organs. However, inter-observer variation is still
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substantial due to requirement of human interpretation of images. A brief summary of the
literature for some key anatomical sites is presented below.
2.7.1 Lung
The inter-observer variation in thoracic tumours is generally large, with substantial
variations in measured volume [24, 57, 58], CI [24], overlap metrics [58, 59] and
dimensions [58]. The most commonly assessed volume in the literature is the GTV for
non small-cell lung cancer (NSCLC), demonstrating large inter-observer variation [24,
31, 57–60]. Delineation uncertainty in lymph node contouring was also found to be
substantial [61, 62]. Inter-observer variation is present in NSCLC GTVs regardless of
whether radiation oncologists or radiologists are contouring, though radiologists were
found to systematically delineate smaller volumes than radiation oncologists [24]. One
study found small overall inter-observer variation in peripheral lung tumours for
stereotactic body radiotherapy (SBRT), with the variation largest in the cranial-caudal
direction [31]. This differs from the large variation observed in other studies due to the
increased visualisation of the tumours due to their location away from the chest
wall.
In theory, four-dimensional CT (4D-CT) might provide better image quality for lung
tumours than conventional CT, however this was not found to impact inter-observer
variation, with one study identifying large deviations [59]. Of the 4D-CT reconstruction
methods, volumes defined on ’mid-position’ reconstructions (reconstruction of every
part of the anatomy in its average position), have the smallest inter-observer variation
[63].
2.7.2 Cervix
Inter-observer variation has been observed in all cervical brachytherapy MRI volumes
(intermediate risk CTV (CTVIR), CTVHR and GTV) defined on MR images [64]. The
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CTVHR was found by Petric et al to have the smallest variability amongst observers and
Dimopoulous et al found the mean volume differences were not significantly different
for this volume [64, 65]. CTVIR was shown to have significant variation, specifically in
the posterolateral directions [64, 65]. Variation in the CTVHR was largest in the cranial-
caudal direction [64]. Volume and overlap metrics were most commonly assessed in
studies assessing inter-observer variation in cervix radiotherapy [64–66]. Inter-observer
variation was present for CT defined contours, however contours were more consistent,
and larger, than when defined on MR images [66].
Contours defined for external beam radiotherapy also exhibit substantial variation when
assessing CTV volumes, overlap metrics and COM [20, 67].
2.7.3 Breast
Whole breast PTVs were found to have substantial inter-observer variation as reported
most commonly by variation in volume [22, 29, 68, 69] and overlap metrics [22, 69, 70].
Although these metrics provides an overall indication of how consistent delineations are,
they do not provide any information about inter-observer variation in specific anatomical
regions. Inter-observer variation was found to vary locally on the target volume [29, 69].
Hurkmans et al found the largest variations in the posterior, cranial and medial directions
of whole breast target volumes [29]. Batumalai et al found that despite high CI for whole
breast target volumes, the medial and posterior edges of whole breast PTVs displayed
marked variation between observers [22].
Another commonly contoured volume in breast radiotherapy is glandular breast tissue.
In general, glandular breast tissue is consistently contoured by observers [37, 45, 71].
However, similar to whole breast volumes, regions of highest inter-observer variation are
the cranial and posterior directions [37].
In post-operative breast target volumes, inter-observer variation was considerable
[71–75]. Inter-observer variation was found to remain substantial, even after contouring
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guidelines implementation [75]. Region specific analysis of surface variations indicate
that inter-observer variation in these volumes is spatially dependent [75]. The presence
of gold fiducial markers or surgical clips on inter-observer variation for lumpectomy
cavities was shown to improve variation [73, 75]. In the pre-operative setting,
inter-observer variation is not substantial [74, 76].
2.7.4 Prostate
Large variability has been observed in the literature for prostate delineation with one
study finding a range in CTV volume from 39.9 to 180.5 cm3 [77]. Volume and volume
overlap metrics were the most common metrics for assessing inter-observer variation
[77–80]. Dimension metrics were also utilised to provide some spatial information [23,
81, 82]. The apex of the prostate exhibited the largest variations for the majority of
studies investigating inter-observer variation for this site [79, 80, 83, 84]. More
generally, large variability was in the craniocaudal length [23, 82] with one study
suggesting that contouring consistency may be improved here if delineation is performed
on all three planes due to CT pixel anisotropy in the sagittal and coronal planes [23]. The
seminal vesicles also exhibited poor consistency in observer delineation [80, 83, 84].
The central portion of the prostate exhibited the highest consistency [83].
Prostate contours defined on CT exhibited greater variation amongst observers as assessed
by volume ratio than contours defined on MRI [78]. The utilisation of both MRI and CT
images when contouring reduced the volume of prostate PTVs as well as the variability
amongst observers when compared to CT alone [80]. Although MRI appears to be the
imaging modality of choice for minimised delineation uncertainty, the exact sequence
should be optimised as Nyhom et al found substantial variability in observers for different
MRI sequences [81].
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2.8 Understanding Inter-Observer Variation -
Dosimetric Impact
This review so far has identified that inter-observer variation is substantial in a number of
anatomical locations and imaging modalities. However, the impact on dosimetric
outcomes is a more relevant clinical endpoint especially since systematic uncertainties
like inter-observer variation are known to shift the dose distribution [6].
There are two main ways to assess the dosimetric impact of inter-observer variation. Both
methods require a cohort of patient images with multiple observers delineating the volume
of interest, and a reference delineation. The first method involves optimising a plan for
each of the observer delineations. The dose volume histogram (DVH) metrics can be
determined for each of the plans on a common reference delineation. The variability in
DVH metrics are indicative of the variation in planning that arises due to inter-observer
variation. The second method requires a single plan optimised to the reference volume.
The variability in DVH metrics as assessed on each of the individual delineations can be
used to quantify the dosimetric impact of inter-observer variation.
Many studies have investigated the dosimetric impact of inter-observer variation. In the
vast majority of studies, substantial variability in dosimetric parameters are observed due
to inter-observer variation. For breast delineations, the dosimetric impact is consistent
for the target volumes, however exhibiting substantial variability for the OARs [85].
Inter-observer variation in lung delineations can lead to unacceptable normal tissue
doses including cardiac dose and mean lung dose [58, 86, 87]. For head and neck
radiotherapy, substantial differences in dose volume histogram parameters were
observed due to inter-observer variation for parotid and brachial plexus contours [88,
89]. Delineation uncertainty in paranasal sinus tumours have been shown to have
considerable impact on delivered dose [90]. Inter-observer variability in brain
delineations resulted in unacceptable plans for 30% of delineations [91]. Also,
inter-observer contouring variability was shown to strongly impact DVH parameters for
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penile bulb contouring [92].
Delineations of the left anterior descending coronary artery have exhibited large inter-
observer variation, resulting in large dosimetric variation [93, 94]. The use of a heart
reference dataset reduced the dosimetric variation in this volume, however in a limited
capacity compared to the whole heart, left main artery and right coronary artery which
were all reduced to less than 1 Gy dosimetric variability [94].
The dosimetric variability in rectum PTVs was observed to be as large as 10% for
three-dimensional conformal radiotherapy plans [95]. Although reduced when
contouring guidelines are implemented, this variability still persists, reducing to
approximately 5% variability in PTV doses. The same trend was observed for volumetric
arc therapy (VMAT) plans, however greater variability was observed. This suggests an
increasing lack of robustness of plans to inter-observer variation as techniques become
more conformal.
Conflicting results are observed for oropharynx cancer. Feng et al found substantial
inter-observer variation in the OAR delineations, but noted minimal dosimetric
difference (< 0.9 Gy) indicating that intensity modulated radiotherapy (IMRT) planning
for this treatment site is robust to inter-observer variation [96]. However, Nelms et al
found that OAR delineations exhibited substantial inter-observer variation, resulting in
substantial dosimetric variation [97]. The conflicting findings may be explained by the
fact that both studies were relatively underpowered, with the former using 3 observers
and 10 patients and the later only 1 patient and 32 observers.
A handful of studies have shown that despite substantial inter-observer variation, the
resulting dosimetric impact is minimal. For breast seroma volumes, PTV margins
adequately accounted for delineation uncertainties, because minimal dosimetric impact
was observed as assessed by the fractional volume contained by the 95% isodose surface
and equivalent uniform dose (EUD) [98]. Inter-observer variation did not result in
clinically significant outcome differences for prostate [84] and gastric cancer PTV
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dosimetric parameters varied minimally [99]. For cervical cancer brachytherapy OARs,
the dosimetric variability was reasonably consistent, however this was primarily due to
the consistency in OAR contouring for this particular study [100]. Other studies have
found up to 2-3 Gy variability in dose over the course of an entire treatment [101] and up
to 10% variation [102] for OAR parameters. Sigmoid delineations exhibit the greatest
variability, most likely due to the varying interpretation of sigmoid anatomy [103].
Cervical cancer brachytherapy CTVHR can exhibit up to 5 Gy variability across a
treatment course [101].
2.9 Minimising Inter-Observer Variation
Attempts to minimise inter-observer variation have been investigated in a number of
studies. Vinod et al reviewed the interventions that have been employed to reduce
inter-observer variability in volume definition in radiation oncology [34]. Non-imaging
interventions can be categorised according to guides and protocols, teaching and
contouring aids. The use of delineation aids such as contrast, radio-opaque wires,
fiducial markers and palpation also aid in reducing contour inaccuracy [22, 29, 104].
Working collaboratively with other colleagues has also been demonstrated to reduce
inter-observer variation [105].
2.9.1 Guidelines or Protocols
A number of studies have suggested that clearly defining protocols will reduce variation
[57, 86, 87, 93, 106–109]. Statistically significant reductions in inter-observer variation
have been shown in lung, breast and OAR delineation when observers followed a
contouring protocol. Sources for contouring protocols in studies that assess these
interventions often include trial protocols [86, 107]. Other sources of protocols come
from advisory groups such as the ESTRO advisory committee on radiation oncology
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practice, who have defined contouring guidelines for non-small cell lung cancer
[110].
For NSCLC CTVs, the utilisation of a phase III trial contouring protocol resulted in a
statistically significant reduction in delineation variation (assessing dimensions,
specifically in the cranial-caudal dimensions) as well as a reduction in the resulting
dosimetric variation (including mean lung dose, as well as heart, spinal cord and
oesophagus DVH parameters) [86]. Another study investigating NSCLC delineation
variability noted that there was statistically significant variation between observers
delineating the GTV. After a 3 year period and a contouring protocol revision, no
statistically significant variations were observed between the same observers [57].
Statistically significant variations in seroma GTVs for partial breast radiotherapy
patients were also eliminated in a cohort of observers who were ’trained’ according to a
contouring protocol compared to observers who were ’untrained’ [106]. A comparison
of inter-observer variation in breast for radiation oncologists and radiation therapists was
performed by Batumalai et al [22]. The inter-observer variation amongst the radiation
therapists was smaller than that of the radiation oncologists. The authors hypothesised
this to be due to the adherence of the contouring protocol. The oncologists were
hypothesised to have weighted their contouring decisions on previous experience higher
than on the protocol.
The utilisation of contouring protocols may result in a reduction of volumes, as was the
case for seroma volumes in partial breast radiotherapy [106]; or an increase in volumes as
was the case for prostatectomy CTVs [107]. In most cases however, observers following
a delineation protocol produced more consistent volumes. Inter-observer variation was
not reduced with the addition of a contouring protocol for breast [75] and lung cancer
radiotherapy patients [60]. Despite the breast seromas showing a reduced variation, the
left anterior descending coronary artery did not improve with guidelines [93].
Lack of protocol compliance for delineation uncertainty was shown to be the biggest
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contributor to poorer patient outcomes in Peters et al [21]. Therefore, there is evidence
that introducing and adhering to a protocol for delineation would reduce inter-observer
variation and improve patient outcomes.
These studies suggest that guidelines and protocols improve consistency in delineation.
The accuracy of the contours after the intervention of contouring protocol is often not
assessed, therefore no comment can be made about the improvement in accuracy with
contouring guidelines.
2.9.2 Teaching
Types of teaching interventions in the literature include didactic lectures, practical
workshops or one-on-one teaching [78, 87, 95, 109, 111–116]. The impact on
inter-observer delineation uncertainty as a result of teaching is variable with studies
conflicting on whether a reduction is observed.
Prostate CTV delineations on CT were not improved despite MRI and CT prostate
anatomy lectures and practical workshops. Participants felts their contouring skills and
confidence had improved, however no significant difference in contour consistency was
observed based on the intervention [112]. Similarly, for NSCLC, no significant
differences were observed before and after an education course for radiation oncology
residents [87]. The authors of this study speculate that the high quality of the contours
prior to education may explain this anomalous finding. For radiation therapists
delineating a range of volumes including prostate, bladder and rectum, large delineation
variations were observed before an education session, and there was little improvement
when repeated after the session [113].
Conversely, Tai et al found that as little as a single ten-minute one-to-one training
session can statistically improve inter-observer variation for cervical oesophageal target
volume delineation [111]. Improved consistency in both CT and MRI based prostate
planning was observed after didactic lectures, practical sessions and with the assistance
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of a prostate atlas [78]. A practical workshop on early stage rectal cancer delineation,
coupled with a delineation atlas, resulted in decreased CTV volumes, reduced caudal
dimensions and reduced surface dimensions in the anterior, lateral, posterior and
sphincter region [115]. Furthermore, the introduction of teaching and contouring
guidelines also showed improved dosimetric consistency for rectal radiotherapy
[95].
Just as there is discordance about whether inter-observer variation improves with
teaching, there is discordance about whether teaching improves delineation accuracy.
Some studies observed an improvement in delineation accuracy as compared to the
’expert’ contours after education, though these results were not significant [87, 113].
Conversely, head and neck squamous cell carcinoma CTVs as delineated by radiation
oncology residents were found to remain sub-optimal despite didactic lectures and hand
on practical sessions [116]. It is difficult to meaningfully assess accuracy in delineation
without a pathological ground truth.
2.9.3 Automatic Segmentation
Manual delineation of target volumes in radiotherapy is both resource and time intensive.
Automatic delineation techniques (auto-segmentation) have been shown to achieve fast,
and consistent segmentation, reducing the presence of inter-observer variation. Auto-
segmentation can be achieved via a number of methods that are summarised in Table
2.2.
At the time of completing the investigations for this thesis, atlas-based segmentation was
the most advanced and frequently used method in medical image segmentation [125].
Hence, Chapter 6 and the following literature review is based on this method. As outlined
in Table 2.2, it is acknowledged that the field has progressed, therefore future work arising
from this thesis would investigate machine-learning based auto-segmentation.
Atlas-based segmentation involves inter-subject registration of retrospective patient
Table 2.2: Summary of automatic segmentation methods [119, 120].
Type Method Limitations
Threshold-Based Regions of uniform brightness are segmented The object and background must have uniform
by applying a threshold to separate the object brightness of distinct grey levels.
and background.
Edge-Based Discontinuities in grey levels or colour are Noise and indistinct discontinuities in grey levels
identified, enabling segmentation based on can result in inaccurate segmentation.
the boundaries of image features.
Region-Based Pixels with similar properties (normally grey Requires optimal selection of properties on which
levels) are grouped together. to cluster pixels otherwise regions may be over/
under segmented
Textural Feature-Based Regions of mutually related elements (texture) Requires optimal selection of texture elements with
are segmented. Tone (pixel intensity properties) which to cluster pixels otherwise regions may be
and structure (spatial relationship of pixels) are over/under segmented
used to define texture.
Model-Based The structure of organs is modelled probabilis- Requires manual interaction to spatially place an
tically as they have a repetitive geometry. This initial model on an image and choose appropriate
model can be used as a constraint in conjunction parameters.
with other segmentation methods.
Atlas-Based Information on anatomy, shape, size etc of Require expert knowledge in building the atlas/
organs for segmentation are compiled in the database and may be limited in segmenting
form of an atlas. This atlas is either used as a complex structures with variable shape.
reference or co-registered with an image to
enable segmentation of a new dataset.
Machine Learning- Artificial neural networks process feature Depends on previous data therefore limited by
Based extraction of images quickly and iteratively to the limitations in data eg image quality. Require
enable fast and accurate segmentation of data. large datasets to begin, however can continually
The neural network learns for previous data and learn.
applies this to a new dataset.
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datasets containing delineations. The result of these registrations is an ’average atlas’
image that is representative of that cohort. Auto-segmentation is achieved by deformedly
registering the atlas to a new dataset and subsequently propagating the delineations.
Atlas-based delineation in the context of inter-observer variation has been investigated in
breast, endometrial, lung and head and neck radiotherapy [52, 69, 117, 118]. All studies
have demonstrated improved consistency in automatic delineations as compared to
manual contours, as well as notable time savings. In the specific case of endometrial
cancer, a commercial based system for atlas-based delineation produced more consistent
target volume delineations, with overlap metrics increasingly significantly compared to
the manual delineations. Breast delineations were shown to have a decreased mean
surface to surface distance when auto-contoured and required minimal editing by the
observers [69]. Head and neck contours were not only shown to be more consistent, but
by comparing to a gold standard contour, auto-contours were shown to be more accurate
when using a commercial auto-contouring system [117].
Other methods of automatic delineation include automatic thresholding of specific
uptake values in PET-CT datasets [52], as well as using a ’gold standard’ breast dataset
deformedly registered to the dataset of interest, enabling observers to study the expert
consensus contour before undertaking their own delineation [121]. The Radiation
Therapy Oncology Group contouring atlas for anorectal CTV is another example of this
method [122]. Note that in this specific case, the use of the ’atlas’ term does not refer to
the definition outlined above.
Ultimately, auto-segmentation techniques require an oncologist to review, and in some
cases edit the contours, thereby re-introducing inter-observer variation. Nevertheless,
these techniques are efficient tools that provide a good starting point for defining target
volumes in radiotherapy [123].
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2.10 Managing Inter-Observer Variation
Accounting for inter-observer variation is increasingly paramount. As techniques and
technologies evolve to reduce set up and motion uncertainties, uncertainty margins are
reducing as well. Delineation uncertainty is less affected by treatment improvements as
it originates in the planning stage of radiotherapy and is limited by imaging capabilities.
Where in the past, larger radiotherapy margins, although not designed for delineation
uncertainty, likely mitigated it to some extent; in recent practice it is inadequately
accounted for. This is especially important for stereotactic techniques where millimetre
margins are being proposed [124]. The risk of geometric miss due to inter-observer
variation is arguably greater than ever.
As outlined earlier in this review, uncertainties in radiotherapy are typically accounted
for by applying an uncertainty margin around the CTV. Although ICRU reports 50 and
62 state that a margin should account for all geometric uncertainties, in practice,
radiotherapy margins often do not include delineation uncertainty [4, 5]. Studies
investigating margin methodologies for radiotherapy, as summarised in Table 2.1, often
do not include a delineation uncertainty component. The few studies that do include this
error in their derivation often assume idealised dose distributions, spherical symmetry of
the error or no shape variations of the target volume [10, 14]. If delineation uncertainty
were to be included in the conventional margin application in the three cardinal
dimensions, it is likely that the error would be inadequately accounted for. This is due to
the spatially varying nature of delineation uncertainties.
The analysis of radiotherapy uncertainties at other points than the cardinal dimensions
has been investigated for the prostate, bladder, cervix and breast [38, 64, 75, 125]. The
cranial-caudal dimension exhibits delineation variability in lung, bladder, Hodgkin
lymphomas and soft-tissue sarcomas, possibly due to the partial voluming effect of
slice-based imaging [30, 31, 125, 126]. Breast target volumes have been shown to have
the greatest inter-observer variability at the posterior and medial borders [22] whereas
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prostate volumes vary most anterior-superior to the apex [38, 127]. Most of these studies
have concluded that anisotropic margins are necessary to adequately account for
spatially varying uncertainties. Three-dimensional, anisotropic extensions of the CTV to
account for spatially varying uncertainties have been proposed [127–129].
Austin-Seymour implemented such a margin for both lung and head and neck sites
however the margin did not consider inter-observer variation in its generation
[129].
Chapter 3
High-Risk CTV Delineation for Cervix
Brachytherapy: Application of
GEC-ESTRO Guidelines in Australia
and New Zealand
This chapter quantifies the variability in CTVHR delineation for HDR cervical cancer
brachytherapy on an Australian dataset and assesses the dosimetric consequences of this
variation on a gold standard target volume. The findings in this chapter contribute to
answering the first aim of this thesis: to understand the impact of delineation uncertainty
on radiotherapy efficacy (Chapter 1.1).
The content in this chapter has been published. The candidate’s contribution to this publication is in the
form of data collection, data analysis and manuscript contribution.
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3.1 Introduction
Image-based brachytherapy is becoming the standard-of-care for cervical cancer. The
GEC-ESTRO group first published guidelines on tumour volume delineation in 2005
[130, 131] and have held regular workshops to educate clinicians on these newly defined
concepts. As with any new technique, interpretation of guidelines may vary with
resulting differences in practice.
The GEC-ESTRO group have documented contouring variability amongst both
GEC-ESTRO radiation oncologists [65] and worldwide including from the United
Kingdom, India and USA [64]. Petric¨ et al evaluated delineation of GTV, CTVHR and
IR-CTV amongst 10 radiation oncologists and compared this with a Simultaneous Truth
and Performance Level Estimation (STAPLE) contour [42] and expert consensus volume
[64]. Delineation variability was noted for all volumes with the CTVHR being the most
consistent volume. This resulted in dosimetric differences with a mean relative standard
deviation (rSD) of 8-10% for both GTV and CTVHR [101].
Australian and New Zealand radiation oncologists have attended GEC-ESTRO
workshops and subsequently implemented image-based brachytherapy in their own
departments. The use of image-based brachytherapy has increased from 27% in 2005
[132] to 65% in 2009 [133]. The main imaging modality has been CT with only one
department using MRI in 2005 increasing to three in 2009. The number of patients with
cervical cancer treated in many departments can be low with 29% of centres treating 10
or less cervical brachytherapy patients per year in 2014 [134].
The practice of cervical brachytherapy is usually limited to one or two radiation
oncologists in a department with limited opportunities for quality assurance on
delineated volumes. The aims of this study were to evaluate translation of GEC-ESTRO
guidelines into the Australian and New Zealand setting by measuring variability in
CTVHR delineation and assessing the dosimetric consequences of this.
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3.2 Methods
Radiation oncologists currently using image-based brachytherapy were identified from a
patterns-of-care survey conducted in 2014 [134] and invited to participate in a target
volume delineation study. Of the 38 centres performing brachytherapy throughout
Australia, New Zealand and Singapore, 21 used MRI at some point in brachytherapy
planning. Clinicians from these 21 centres were invited to participate with those from 10
centres agreeing to do so. This included nine radiation oncologists and one radiation
therapist with extensive experience in gynaecological brachytherapy. In addition, two
radiologists specialising in pelvic MRI with experience in radiation therapy volume
delineation also took part in the study.
The study was approved by the institutional ethics board. The datasets of 10 consecutive
cervical cancer patients undergoing brachytherapy at a single institution were
de-identified for use. The MRI images were acquired on fraction 1 or 2 of brachytherapy
on a 3-Tesla wide bore MRI system (MAGNETOM Skyra, Siemens Healthcare,
Erlangen, Germany) with 45 mT/m gradient strength and 200 T/m/s slew rate. Oblique
sagittal and coronal T2 weighted half-fourier acquisition single-shot turbo spin echo
(HASTE) and T2 weighted turbo spin echo (TSE) oblique axial imaging of the
brachytherapy applicator set in vivo were acquired in all patients. The applicators used
were tandem and ovoids in eight cases and tandem and cylinder in two cases.
Participants were given clinical details, a diagnostic MRI report of initial tumour extent,
’Examination Under Anaesthesia’ findings at brachytherapy and a schematic diagram of
findings at brachytherapy. Participants were asked to contour CTVHR based on this
information. This volume was chosen as CTVHR is the most relevant volume to delineate
in image-based brachytherapy. It contains macroscopic tumour at time of brachytherapy
[130] and has a dose-response relationship with local control [65]. Two reference
volumes were created for comparisons: a STAPLE [42] and a manually generated
consensus volume (consensus) between two radiation oncologists and a radiologist. The
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consensus contour was created after all individual contouring had been completed. The
STAPLE contour is a probabilistic estimate of the ’true contour’ computed from the
manually drawn contours by measuring the performance of each individual
segmentation.
Contour comparisons were performed using volume (mean and SD), the DSC and
MASD. The DSC is a measure of spatial overlap between two volumes as defined by
2(A∩B)/A+B where 0 is no agreement and 1 is perfect agreement. The MASD is the
average distance between surface voxels [32, 39]. A DSC close to 1 and MASD close to
0 mm is associated with minimal variability in delineation. For the purposes of this
study, we defined DSC ≥ 0.7 and MASD ≤ 5 mm as showing good agreement in volume
delineation [64]. Dosimetry was reported as mean values (µ) for the 12 observers with
SD (σ ). To compare the variability in dosimetry, rSD = σ /µ .
Two 8 Gy single fraction plans optimised to the consensus and STAPLE contours,
respectively, were generated for each patient dataset by a radiation therapist and checked
by a radiation oncologist. Standard applicator loadings were used to generate a
conventional plan dosed to Point A. This was optimised to the consensus contours with
the aim of ensuring a minimum of 8 Gy to CTVHR dose to 90% of the volume (D90).
The OAR tolerances were based on combined external beam (45 Gy/25 fractions) and
brachytherapy doses, limiting bladder equi-effective dose (EQD2) to 2 cm3 of the
volume (D2cm3) to ≤ 90 Gy and rectum and sigmoid EQD23 D2cm3 ≤ 75 Gy. This
equated to bladder D2cm3 ≤ 5.91 Gy and rectum and sigmoid D2cm3 ≤ 5.34 Gy for this
single fraction plan. If the OAR (bladder, rectum, sigmoid) DVHs exceeded 110% of
acceptable dose, then a lower dose to the CTVHR was accepted. This plan was
subsequently applied to the STAPLE contour and optimised using the same criteria. For
each case, D90 and dose to 100% of the volume (D100) coverage of individual
participant’s CTVHR by the consensus and STAPLE plans was assessed.
Table 3.1: Mean ± SD of CTVHR volumes, MASD and DSC.
Case Stage CTVHR STAPLE reference (mean) Consensus reference (mean) STAPLE vs Consensus
Volume (mm) MASD (mm) DSC MASD (mm) DSC MASD (mm) DSC
1 T3bN0M0 60.3 ± 19.2 3.56 ± 1.92 0.71 ± 0.15 2.80 ± 1.45 0.72 ± 0.09 3.41 0.72
2 T2bN1M0 37.5 ± 15.6 2.29 ± 1.39 0.79 ± 0.08 2.45 ± 1.94 0.76 ± 0.11 2.18 0.77
3 T2bN1M0 55.7 ± 14.7 4.54 ± 2.72 0.70 ± 0.18 5.22 ± 3.43 0.65 ± 0.12 7.39 0.58
4 T3bN0M0 63.9 ± 35.3 11.01 ± 6.38 0.53 ± 0.23 9.82 ± 7.48 0.47 ± 0.15 21.1 0.25
5 T3bN1M0 39.5 ± 21.4 3.29 ± 1.96 0.71 ± 0.11 4.05 ± 3.72 0.69 ± 0.14 4.90 0.64
6 T1b1N1M0 30.1 ± 9.5 3.75 ± 1.61 0.74 ± 0.11 3.87 ± 3.03 0.74 ± 0.14 5.29 0.62
7 T4N0M1 142.3 ± 71.6 13.30 ± 13.14 0.58 ± 0.30 13.72 ± 13.04 0.51 ± 0.30 16.32 0.57
8 T3bN1M0 100.6 ± 22.1 2.47 ± 0.88 0.85 ± 0.05 2.61 ± 1.17 0.81 ± 0.05 3.01 0.78
9 T2aN0M0 14.9 ± 4.2 1.95 ± 0.65 0.78 ± 0.08 1.84 ± 0.95 0.77 ± 0.07 3.27 0.67
10 T1b2N1M0 30.1 ± 9.5 3.12 ± 1.46 0.79 ± 0.07 3.02 ± 2.28 0.79 ± 0.09 4.43 0.74
Mean 4.93 ± 3.21 0.72 ± 0.14 4.94 ± 3.85 0.69 ± 0.12 7.13 ± 6.37 0.63 ± 0.15
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3.3 Results
The stage distribution of patients included two patients with International Federation of
Gynaecology and Obstetrics (FIGO) stage IB cancers, one FIGO stage IIA, two FIGO
stage IIB, four FIGO Stage IIIB and one FIGO stage IVA (Table 3.1). Good responses
to external beam radiotherapy noted at the time of examination for brachytherapy were
documented for all patients except for patients 7 and 8. Two patients (1 and 9) were
treated with a tandem and cylinder due to lower vaginal extension of cancer or inability
to fit ovoids. The remainder were treated with tandem and ovoid applicators. The range
of volumes contoured by the observers is shown in Figure 3.1. The largest variation
volumetrically was seen for patient 7 who had a FIGO IVA cancer extending into adjacent
bowel and the smallest variation for patient 9 who had a FIGO IIA cancer. There did
not appear to be any relationship between the range of volumetric variation and initial
tumour stage or response to external beam radiation therapy. One observer (observer A)
contoured the largest or second largest volume in 6/10 cases and another (observer E)
the smallest or second smallest volume in 7/10 cases (Figure 3.1). Visually the greatest
variation in contouring occurred in the cranial and caudal directions, even in patients
where delineation was more consistent. Representative examples for patients with low
and high concordance indices are shown in Figures 3.2 and 3.3.
A mean DSC ≥ 0.7 was achieved in 8/10 cases when compared to the STAPLE reference
and 6/10 cases when compared to the consensus reference (Table 3.1). A mean MASD
≤ 5 mm was recorded in 8/10 cases when compared to the STAPLE reference and 7/10
cases when compared to the consensus reference (Table 3.1). No systematic differences
were noted between radiation oncologists/therapist and radiologists in terms of DSC and
MASD. The concordance between the STAPLE and consensus reference volumes is also
shown. Only four patients had DSC ≥ 0.7 and six patients MASD ≤ 5 mm.
For individual patients, the percentage of participants achieving DSC ≥ 0.7 was 25% and
8% for patient 4, 58% and 33% for patient 3, and 42% and 42% for patient 8, compared to
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Figure 3.1: CTVHR volume in cubic centimeters (cc) delineated by observers.
Figure 3.2: CTVHR contours on Patient 4 where there was low concordance in
delineation. The DSC was 0.47 and 0.53 and the MASD was 9.8 mm and 11.0 mm
with reference to the consensus and STAPLE contours respectively.
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Figure 3.3: CTVHR contours on Patient 9 where there was high concordance in
delineation. The DSC was 0.77 and 0.78 and the MASD was 1.84 mm and 1.95 mm
with reference to the consensus and STAPLE contours respectively.
the STAPLE and consensus references, respectively. For the remainder of the patients, the
percentage achieving DSC ≥ 0.7 was 50% or greater. For patient 9, 100% of participants
achieved DSC ≥ 0.7 compared to both reference volumes. A similar pattern was seen
with MASD. Considering each individual contour (n = 120), a DSC ≥ 0.7 was achieved
in 67% and 63% and MASD≤ 5 mm achieved in 75% and 73% compared to the STAPLE
and consensus references, respectively.
A consensus and STAPLE plan were optimised for each patient. The planning aim of
CTVHR D90 = 8 Gy was met in five patients for the consensus plan and two patients for
the STAPLE plan (Table 3.2).
It was not achieved in the other patients due to unacceptably high doses to organs-at-risk
and large CTVHRs which could not be covered by non-interstitial brachytherapy. When
the consensus and STAPLE plans were applied to individual participant contours, dose
variation in D90 and D100 was seen. The smallest range of D90 (≤ 3 Gy) was seen for
patients 1, 9 and 10, whilst the largest range (> 7 Gy) was seen in patients 4 and 7 (Figure
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Table 3.2: Mean ± SD of CTVHR D90. The dose achieved refers to the CTVHR D90
dose achieved in the STAPLE and consensus plans, which were then applied to individual
observer contours.
Case STAPLE reference (Gy) CONSENSUS reference (Gy)
Dose Achieved CTVHR D90 Dose Achieved CTVHR D90
1 4.05 4.15 ± 0.54 3.91 4.18 ± 0.59
2 9.52 9.83 ± 1.30 10.92 10.37 ± 1.36
3 4.68 6.37 ± 1.36 6.28 6.27 ± 1.56
4 2.66 7.38 ± 3.26 8.45 6.16 ± 2.81
5 6.64 7.91 ± 1.90 8.92 7.04 ± 1.60
6 6.28 7.74 ± 1.86 8.42 7.74 ± 1.86
7 1.17 3.07 ± 2.85 1.38 3.02 ± 3.11
8 5.59 6.11 ± 1.09 6.15 6.01 ± 1.03
9 8.03 8.64 ± 0.57 8.63 8.37 ± 0.63
10 7.18 7.34 ± 0.83 7.68 7.12 ± 0.85
Mean 5.58 6.84 ± 1.56 7.07 6.62 ± 1.54
3.4).
There was less variation in range of dose seen for D100. The smallest range of D100 (<
2 Gy) was seen in patient 1 and the largest range (> 4 Gy) in patients 2, 4, 5 and 6 (Figure
3.5). If we consider just the dose range for the middle 50% of participants, the greatest
range for both D90 and D100 was seen in patient 4 and the least range in D90 for patients
1, 9 and 10 and D100 patient 1 and 7 for both STAPLE and consensus plans. Significant
outlier doses were seen in D90 for patients 1, 7, 8, 9 and 10 and in D100 for patients 2, 7
and 10. The outlying observers were different for each patient.
The mean rSD of doses when STAPLE and consensus plans were applied to individual
observer contours is shown in Figure 3.6. In most cases the mean rSD for CTVHR D90
was less than 25% and D100 less than 35%. Values were greater for patients 4 and 7.
The average mean rSD across all patients was 27% and 34% for the STAPLE CTVHR
D90 and D100, respectively, and 28% and 35% for the consensus CTVHR D90 and D100.
Delineation uncertainty resulted in an average dosimetric uncertainty of ±1.6 Gy per
fraction for the STAPLE plan and ±1.5 Gy per fraction for the consensus plan based on
an 8 Gy prescribed fraction (Table 3.2).
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Figure 3.4: CTVHR D90 doses for individual contours with application of STAPLE and
consensus plans.
Figure 3.5: CTVHR D100 doses for individual contours with application of STAPLE
and consensus plans.
CHAPTER 3. CTVHR DELINEATION FOR CERVIX BRACHYTHERAPY 43
Figure 3.6: Mean rSD of doses when STAPLE and consensus plans where applied to
individual observer contours.
3.4 Discussion
This study measured inter-observer variability in target volume delineation and resultant
dosimetric effects for cervical brachytherapy in the Australian and New Zealand setting.
We used unselected sequentially acquired patient datasets at a single centre. This is only
the second study using 3-Tesla MRI to evaluate contouring variability for cervix
brachytherapy, the previous one being from USA [66].
We found that in the majority of cases, delineation of CTVHR was consistent, as defined
by DSC ≥ 0.7 and MASD ≤ 5 mm. This is in contrast to Viswanathan et al [66] who
evaluated delineation of CTVHR on 3-Tesla MRI and CT for three cases using 23
observers. CIs were poor ranging 0.44 - 0.48 for CT and 0.38 - 0.42 for MRI, and were
significantly higher for CT than MRI. This may be due to the larger number of observers
in that study. In the current study the comparison metrics were acceptable in a slightly
greater proportion of patients in reference to the STAPLE reference, as this volume is a
probabilistic estimate of true volume generated from all observers. The consensus
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reference was drawn by collaboration between two experienced radiation oncologists
and a radiologist specialising in pelvic MRI.
Other studies published by the GEC-ESTRO group have used lower strength MRIs for
imaging, either 0.2-Tesla or 1.5-Tesla [64, 65]. Dimopoulos et al. evaluated
inter-observer variation in delineation of GTV, CTVHR and CTVIR in 19 patients with
two observers [65]. The CI for GTV, CTVHR and CTVIR were 0.5, 0.6 and 0.6,
respectively, showing moderate variation even amongst two experienced radiation
oncologists working at centres which developed the GEC-ESTRO guidelines.
Petric et al [64] conducted a study involving observers from 10 institutions worldwide
using MRI datasets of six patients. Two reference contours were used for comparisons, a
STAPLE contour and an expert consensus contour. The mean CI for CTVHR delineation
was 0.76 for the STAPLE reference and 0.72 for the consensus reference which is slightly
higher than the respective indices of 0.72 and 0.69 measured in the current study.
The choice of a reference volume can influence the results of both volume comparisons
and dosimetric evaluation. The gold standard of a pathologically defined volume is
impossible in this context hence surrogate volumes are chosen for reference. The choice
of both an expert consensus volume and STAPLE volume is common. Our study shows
that concordance of these volumes with each other is in fact moderate at best and similar
to comparisons between two experienced GEC-ESTRO clinicians [65].
Visually, we observed that the greatest variation in delineation was in the cranio-caudal
direction. This is similar to findings reported by Dimpoulos et al [65] and Petric et al [64].
We also noted some systematic differences in contouring with one observer consistently
delineating larger volumes and one smaller volumes compared to the average.
The clinical impact of delineation variability can be evaluated by assessing the effect on
dosimetry. Ideally a plan would be generated for each observers contour and applied to
the consensus and STAPLE volumes to evaluate dose to target volumes and organs-at-risk.
However, this is a considerably time consuming process.
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Hence, the method chosen for dosimetric evaluation was identical to that published by
Hellebust et al [101] whereby plans optimised to two reference contours, STAPLE and
consensus were applied to individual observer contours. We found that the mean rSD
varied from 27 to 28% for CTVHR D90 and from 34 to 35% for CTVHR D100. This is
greater than that reported by Hellebust et al who found a mean rSD of 9-10% for CTVHR
D90 and 17-19% for CTVHR D100 [101]. Dimopoulos et al [65] also evaluated dosimetry
for plans based on contours by two observers and found no significant differences in the
D90 or D100 for any of the volumes.
The average measured dosimetric variation was 1.5-1.6 Gy for a single brachytherapy
insertion. The range of dosimetric variability was in most cases similar for the STAPLE
and consensus plans. This may be a consequence of the applicators used which provided
limited opportunities for dose optimisation for larger tumours due to lack of interstitial
needles. Inter-patient variability was noted for whether planning aims were met. Dose
variation was independent of initial disease stage and tumour response seen at the time of
brachytherapy.
Despite acceptable volume concordance metrics for the majority of patients in this study,
relative dose variation could be clinically significant. The effect of this uncertainty will
increase with multiple fractions of brachytherapy. If plans are optimised per observer to
improve this, one would expect the range of OAR doses to vary widely. This was not
measured in this study as the organs-at-risk were delineated by a sole radiation therapist.
Other studies have shown that rSD for D2cm3 doses varies from 5 to 16% for bladder,
7 to 11% for rectum and 11 to 34% for sigmoid with larger variation being reported for
delineation on CT [100–103]. Organ-at-risk volumes are often delineated by radiation
therapists and should be checked by radiation oncologists prior to plan approval.
This study has some limitations. Of note there were no interstitial applicators used, and
in two cases a tandem and cylinder were inserted and so dose coverage was compromised
in some instances. The patients were unselected and so represent a typical clinical cohort
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in whom the planning aims were not always met. There were only 10 patient datasets
used and only one volume delineated (CTVHR). However, both the number of datasets
and observers is similar to other published studies. The choice of a single volume was to
prevent contourer fatigue. The assessment of variation in dosimetry remains valid even if
planning aims cannot be met.
Brachytherapy for cervical cancer remains a small practice in most Australian and New
Zealand radiation oncology departments. Given the variation documented, it may be
useful to involve a peer radiation oncologist or radiologist to aid in target volume
delineation. Accurate volume delineation is crucial to the practice of brachytherapy and
this may potentially suffer if performed infrequently. Treatment at low volume centres
(< 10 patients per year) can result in poor quality brachytherapy [135]. The
Gynaecology Oncology Radiation Oncology Collaboration specialty interest group of
the Royal Australian and New Zealand College of Radiologists will have a role in
ensuring quality brachytherapy treatment for cervical cancer in the future.
Chapter 4
Dose Planning Variations Related to
Delineation Uncertainties in
MRI-Guided Brachytherapy for Locally
Advanced Cervical Cancer
This chapter assesses the dosimetric variation that arises from inter-observer variation in
HDR cervical brachytherapy. This chapter expands on Chapter 3 by investigating the
dosimetric differences arising when individual plans are optimised to individual observer
contours. The findings in this chapter contribute to answering the first aim of this thesis:
to understand the impact of delineation uncertainty on radiotherapy efficacy (Chapter
1.1).
The content in this chapter is in preparation for publication. The candidate’s contribution to this publication
is in the form of data generation, collection and analysis as well as authorship of manuscript.
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4.1 Introduction
Image-guided adaptive brachytherapy (IGABT) is the standard-of-care in the treatment of
locally advanced cervical cancer, with MRI the imaging modality of choice. The excellent
patient outcomes of IGABT for cervical cancer has been demonstrated in the EMBRACE
studies (Retro-EMBRACE, EMBRACE and EMBRACE II) [136–140]. These studies are
based on GEC-ESTRO guidelines on contouring and dose reporting [130, 131]. However,
uncertainty in target volume delineation remains, regardless of adherence to protocols.
The location and magnitude of delineation uncertainty has been extensively investigated
for a number of anatomical sites in both external beam radiotherapy and brachytherapy
contexts [21, 97, 107, 141]. The sharp dose gradients that characterise brachytherapy may
result in an increased dosimetric impact of delineation uncertainty including the risk of
geographical miss.
Hellebust et al investigated the dose reporting uncertainties due to contouring variation,
when a single ’gold standard’ cervical cancer brachytherapy plan was assessed on
multiple contour sets delineated by 10 observers [101]. The observers were from centres
participating in the EMBRACE study [64, 137]. A reported dosimetric difference of ± 5
Gy EQD210 was seen for the high risk clinical target volume and between ± 2-3 Gy
EQD23 for the organs at risk (OARs).
The present study utilises the same gynaecological MRI brachytherapy dataset from
Hellebust et al [101], but investigates the variation in dose planning that arises from
target delineation uncertainties when individual plans are optimised to each individual
contour set. As an additional aim, this study investigates whether there are correlations
between contour variation metrics and dosimetric outcomes when plans are optimised to
each individual contour [35].
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4.2 Methods
4.2.1 Dataset
The material used for this analysis is from a study on contouring uncertainties performed
in the frame of EMBRACE, completed and published in 2013 [64, 137]. The dataset
consisted of MR images from six patients treated for FIGO stage IIb-IIIb cervical cancer.
The patients were selected to represent common clinical scenarios and to reflect typical
challenges relevant for contouring.
4.2.2 Target Volume Definition
Images were distributed to institutions that participated in the EMBRACE study and hence
with considerable experience in MRI-based cervical brachytherapy. One observer from
each participating institution delineated the target volumes and relevant OARs according
to the GEC-ESTRO recommendations [130, 131]. Specific volumes contoured included
the residual GTV, CTVIR, CTVHR, bladder, rectum and sigmoid.
A group of experts including four experienced radiation oncologists generated a gold
standard expert consensus (EC) set of contours (targets and OARs). Additionally, the
STAPLE was generated using in-house software [142] to provide a probabilistic estimate
of the ’true’ volume from the observer contours.
4.2.3 Treatment Planning
This study was performed retrospectively and is concerned with the brachytherapy
component of a virtual treatment course consisting of combined external beam
radiotherapy (45 Gy in 25 fractions) and four brachytherapy fractions of 7.2 Gy each
(85.5 Gy EQD210 in total). The brachytherapy component comprised treatment via a
ring and tandem applicator with interstitial needles inserted at appropriate
Table 4.1: Planning constraints as per EMBRACE II protocol [64].
D90 CTVHR D98 CTVHR D98 GTV D98 CTVIR D2cm3 Bladder D2cm3 Sigmoid D2cm3 Rectum Recto-vaginal
EQD210 EQD210 EQD210 EQD210 EQD23 EQD23 EQD23 point EQD23
Soft constraints > 90 Gy > 75 Gy > 95 Gy > 60 Gy < 80 Gy < 70 Gy < 65 Gy < 65 Gy
< 95 Gy
Hard constraints > 85.5 Gy - > 90 Gy - < 90 Gy < 75 Gy < 75 Gy < 75 Gy
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locations for the specific disease. Applicator specifications for each patient are presented
in Table A.1.
For each observers set of contours, a treatment plan was individually optimised resulting
in 12 plans per patient (10 observer contours, EC contour and STAPLE contour). Each
patient had a common applicator reconstruction for each plan. Plan optimisation was
achieved by the same physicist with review by an oncologist specialising in cervical
cancer treatment. The constraints used during treatment plan optimisation (soft and hard)
were in line with the EMBRACE II protocol [137, 143] as outlined in Table 4.1. As a
soft constraint, needle loading was minimised to less than 20% of the total dwell-weight.
An additional focus was placed on de-escalating dose to the upper vagina as per
EMBRACE II protocols and emerging evidence [137, 144–146]. The ratio of the vaginal
total reference air kerma (TRAK) to the total TRAK was aimed, where possible, to be
kept below 30-40%.
4.2.4 Inter-observer Variation Analysis
The inter-observer variation of the contours used in this study and the impact on reported
dose arising from a gold standard plan has been assessed previously [64, 101]. This study
aims to investigate the planning variation due to inter-observer delineation variation by
optimising plans to specific delineations. The fundamental methodology difference of this
study and the previous [101] is outlined in Figure 4.1. In the previous study, contouring
variation resulted in reporting uncertainties when a single ’gold standard’ plan is applied
to all contour sets. In the current study, firstly, plans were optimised to each individual
contour set, representing the variation in dose that would have been reported. All together
72 plans were made (10 contours sets plus EC and STAPLE for 6 patients). Secondly,
these plans were applied to the EC and STAPLE contour sets and the variation in the dose
that would have been delivered were found.
Treatment plans and DVH data were analysed using an in-house MATLAB code [147].
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Figure 4.1: Methodology difference between this study (left) examining uncertainties in
planned dose due to delineation uncertainties and Hellebust et al [101] (right) examining
dose reporting variations due to delineation uncertainties. The arrows point to the
contours on which the dosimetric parameters were calculated.
For a single fraction, D90 and the dose to 98% of the CTVHR (D98) were determined for
each optimised plan [148]. CTVIR and GTV D98 were also determined for each plan.
D2cm3 of the volume was determined for the EC and STAPLE OARs (bladder, rectum
and sigmoid) in the same fashion.
Incorporating the brachytherapy and external beam components of treatment, the total
EQD2 was calculated for each of the DVH parameters with α/β = 10 Gy for target
volumes and α/β = 3 Gy for OARs. For each DVH parameter, the mean and SD were
determined. To assess the impact of inter-observer uncertainty over a typical
brachytherapy course the rSD relative to the total brachytherapy dose was
determined.
4.2.5 Correlation Analysis
The correlation between contouring metrics and dosimetric parameters was assessed to
investigate whether contouring decisions have an impact on the dosimetric outcome.
Contouring metrics as calculated in reference to both the STAPLE and consensus
volumes include volume, shift in COM, CI [149] and maximum directions in the
cardinal directions (MD-X, MD-Y, MD-Z where X is lateral, Y is anterior/posterior and
Z is superior/inferior). Dosimetric parameters include the DVH parameters outlined
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above. The two-sided Spearman’s nonparametric rank-correlation coefficient (ρ) was
determined for all metrics with significance indicated by p < 0.05 using IBM SPSS
Statistics v19 [150].
4.3 Results
For details on the delineations, including an assessment of inter-observer variation, the
reader is referred to Petric et al [64]. One of the plans generated was not assessed as
it was incorrectly exported and subsequently inaccessible. The following presents the
results of the remaining 71 plans.
4.3.1 Treatment Planning
Technical details of the generated treatment plans are presented in Table 4.2. Prescribed
CTVHR D90 for each plan based on the individual contours are presented in Table 4.3.
The other resulting DVH parameters are listed in Table A.2. As described above, these
figures represent the dose parameters that would have been reported due to contouring
variation. 80.0% (57 out of 71) plans fulfilled the hard constraint of CTVHR D90 >
85.5 Gy EQD210). Furthermore, 45.0% (32 out of 71) plans fulfilled the soft constraint of
CTVHR > 90 Gy EQD210. Of the plans that did not achieve the hard constraints, 7 of these
occurred for a single patient in which the proximity of the OARs in relation to the high
dose region was especially challenging. Common planning problems arose when trying
to achieve the soft constraint to the CTVIR D98 without exceeding the bladder tolerance.
Although no plan exceeded the hard constraint for the bladder, the soft constraint was
exceeded in 57.7% (41 out of 71) of plans.
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Table 4.2: Technical details of generated treatment plans. These values are for a de-
commissioned source therefore do not reflect a clinical treatment. This table is provided
to enable relative difference comparisons between plans
Patient Total Reference Air Kerma (cGy) Total Dwell Time (s) Vaginal Loading (%)
1 Mean 1.93 424.75 21.28SD 0.09 20.60 5.31
2 Mean 1.24 1459.48 33.37SD 0.09 107.08 5.36
3 Mean 1.54 1804.73 31.26SD 0.14 162.30 10.36
4 Mean 1.68 1720.98 22.87SD 0.09 608.40 2.99
5 Mean 1.81 2120.05 34.82SD 0.11 134.53 3.65
6 Mean 2.02 2374.94 23.27SD 0.08 90.21 3.67
Table 4.3: Prescribed CTVHR D90 (Gy) for plans optimised to each observer contour.
Italic font for the plans not fulfilling the hard constraint.
Patient 1 2 3 4 5 6
Master 91.0 90.6 88.3 87.1 87.6 92.1
STAPLE 90.6 89.8 85.8 81.9 90.5 83.8
Observer 1 90.6 89.3 86.3 81.9 91.0 85.9
Observer 2 90.1 96.6 80.0 85.6 84.8 79.9
Observer 3 91.5 92.3 - 88.9 92.0 85.6
Observer 4 94.2 93.6 89.8 86.8 93.6 85.9
Observer 5 89.9 89.4 78.9 85.9 90.5 67.3
Observer 6 89.7 85.0 85.7 76.2 91.0 87.4
Observer 7 90.0 90.2 86.0 80.3 90.5 87.4
Observer 8 94.7 92.4 92.3 73.0 95.0 85.5
Observer 9 94.5 92.5 91.6 80.5 91.0 86.8
Observer 10 93.6 90.6 90.0 83.3 90.3 86.0
Mean (Gy) 91.7 91.0 86.8 82.6 90.7 84.5
SD (Gy) 2.0 2.8 4.3 4.7 2.6 6.1
rSD (Gy) 4.1 6.0 10.2 12.2 5.6 15.1
Figure 4.2: CTVHR D90 EQD210 for plans optimised to different contours applied on (a) STAPLE contour and (b) expert consensus contour.
The order of observers is identical across both panels. The rSD is for the brachytherapy fractions only.
Table 4.4: Mean, SD and rSD of EQD2, averaged across all observers for each patient. The rSD is reported as percentages of the brachytherapy
treatment only.
STAPLE EC
Case 1 2 3 4 5 6 Mean 1 2 3 4 5 6 Mean
CTVHR Mean (Gy) 91.0 87.6 86.2 77.3 87.9 82.9 85.5 89.3 94.0 87.0 85.4 89.8 91.7 89.5
D90 SD (Gy) 3.2 4.2 2.0 4.9 4.8 1.4 3.4 2.7 3.5 1.8 3.6 4.1 1.6 2.9
rSD (%) 6.9 9.7 4.8 14.7 11.0 3.7 8.5 6.0 7.0 4.1 8.8 8.9 3.3 6.4
CTVHR Mean (Gy) 82.7 78.5 76.8 65.6 78.0 71.8 75.6 81.6 82.9 78.4 73.3 80.2 77.8 79.0
D98 SD (Gy) 2.9 4.1 1.8 3.5 5.9 1.7 3.3 2.4 2.8 1.6 2.6 4.7 2 2.7
rSD (Gy) 7.5 12.1 5.5 16.5 17.5 6.2 10.9 6.5 7.2 4.6 9.1 13.2 5.9 7.8
CTVIR Mean (Gy) 63.1 60.0 58.2 55.0 59.5 57.8 58.9 62.7 61.5 60.0 56.7 61.1 61.8 60.6
D98 SD (Gy) 1.7 1.8 0.9 1.5 2.3 0.7 1.5 1.5 1.5 1.1 1.1 2.1 0.8 1.4
rSD (%) 8.9 11.3 6.2 13.5 15.4 4.9 10.0 8.3 9.0 7.1 9.1 12.2 4.5 8.4
GTV Mean (Gy) 92.3 91.5 98.8 86.8 90.7 83.4 90.6 97.8 94.8 98.4 115.7 107.0 84.3 99.7
D98 SD (Gy) 2.8 6.6 2.7 3.3 3.5 2.7 3.6 2 3.1 2.6 5 4.3 3 3.3
rSD (%) 5.7 13.9 4.9 7.7 7.4 6.8 7.7 3.7 6.0 4.8 7.0 6.8 7.5 6.0
Bladder Mean (Gy) 78.0 82.9 79.0 88.7 82.0 87.0 83.0 77.8 80.2 75.0 85.3 82.7 86.5 81.2
D2cm3 SD (Gy) 1.7 2.7 5.0 4.7 4.9 2.7 3.6 1.8 2.7 4.1 4.4 4.9 2.7 3.4
rSD (%) 4.9 6.9 13.9 10.4 12.7 6.3 9.2 5.2 7.4 13.0 10.6 12.5 6.2 9.1
Rectum Mean (Gy) 55.0 62.9 55.9 68.8 60.4 69.6 62.1 54.1 62.4 54.5 66.5 60.3 66.7 60.7
D2cm3 SD (Gy) 1.5 2.9 1.9 1.7 2.2 2.4 2.1 1.4 2.7 1.7 1.5 2.2 2.0 1.9
rSD (%) 13.0 14.7 14.8 6.6 12.8 9.2 11.9 12.7 14.2 15.2 6.4 12.9 8.7 11.7
Sigmoid Mean (Gy) 70.9 50.6 72.2 55.9 70.0 67.6 64.5 68.2 50.4 68.6 55.1 66.6 65.9 62.5
D2cm3 SD (Gy) 1.8 0.6 1.2 1.1 3.0 1.4 1.5 1.6 0.5 1.1 1.0 2.2 1.1 1.2
rSD (%) 6.4 7.6 4.3 8.7 11.2 5.6 7.3 6.2 7.0 4.3 8.7 9.4 4.8 6.7
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4.3.2 Inter-observer Variation Analysis
When individual contour based plans were applied to the gold standard contours (EC or
STAPLE), the dosimetric variability can be seen in Figure 4.2. Tables 4.4 and A.3 provide
further details for all contours and dosimetric parameters. The rSD in STAPLE CTVHR
D90 across patients ranged between 3.7 - 15.1% and for the EC CTVHR D90, ranged
between 3.4 - 9.0%. The rSD represents the dosimetric variability of the brachytherapy
component of the treatment course only. This gives a representation of the variable of the
delivered dose that may arise clinically depending on the clinician who delineates. The
dosimetric variability depends on the gold standard used for analysis, with a greater range
in variability observed for the STAPLE contours.
4.3.3 Correlation Analysis
Table 4.5 shows the Spearmans non parametric rank correlation coefficient and
significance, relating the dosimetric and contouring parameters of the CTVHR. The
statistics for the other target contours and the OARs are shown in Tables A.4 and A.5. In
summary, maximum dimensions in the cardinal directions correlate most frequently with
dosimetric changes.
4.4 Discussion
For a single fraction of HDR intra-cavity cervix IGABT, the total dosimetric uncertainty
in CTVHR D90 can reach 12% [151, 152]. Factors that contribute to this dosimetric
uncertainty include source strength specification (2%), treatment planning (3%), medium
dosimetric corrections (1%), dose delivery (4%) and inter-fraction/intra-fraction changes
(11%). Source strength specification impacts all levels of treatment planning requiring
the methodology to be well documented and uniformly agreed upon in the brachytherapy
community. Treatment planning uncertainties arise when adjusting input dosimetry
Table 4.5: Spearmans non-parametric correlation coefficient results for the EC and STAPLE CTVHR contour. Statistically significant results
shown in bold italics.
x COM y COM z COM COM MD-X MD-Y MD-Z Vol CI
ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig
EC D90 0.21 0.08 -0.01 0.94 0.09 0.46 0.03 0.82 -0.19 0.11 -0.07 0.59 0.05 0.68 -0.03 0.83 -0.17 0.17
EC D98 -0.16 0.19 0.02 0.87 -0.14 0.25 -0.06 0.64 -0.38 < 0.01 -0.39 < 0.01 -0.25 0.04 -0.32 0.01 0.04 0.72
STAPLE
D90 0.21 0.09 -0.2 0.87 0.09 0.47 0.14 0.26 -0.19 0.12 -0.27 0.02 -0.18 0.13 -0.16 0.17 0.21 0.09
STAPLE
D98 0.2 0.1 -0.04 0.72 0.08 0.51 0.1 0.39 -0.27 0.02 -0.34 < 0.01 -0.23 0.06 -0.25 0.04 0.21 0.08
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parameters derived under reference conditions, for the patient specific circumstances.
Treatment planning uncertainties will vary with source type and position relative to the
source and can be minimised with fractionation. Medium dosimetric corrections account
for the deviation of the patient specific conditions from uniform water. This includes the
presence of high density materials and tissue/air interfaces near the treating volume.
Uncertainties are dependent on the position of heterogeneities relative to the source.
Dose delivery uncertainties include deviations in positional accuracy of the source as
defined by the applicator positioning and afterloader performance. The temporal
accuracy of the source is also included in this category. Inter- and intra-fraction changes
are the largest contributors to the total dosimetric uncertainty, mainly due to contouring
uncertainty [151, 152]. It is therefore especially important to investigate the dosimetric
impact of inter-observer contouring variation in cervical brachytherapy treatments. With
sharp dose gradients abutting normal tissue, a small change in the dose distribution due
to inaccurate contouring may have substantial implications for patient treatment.
This study investigated the differences in prescribed dose arising from planning variation
when plans are optimised to individual contours. Hellebust et al investigated the
variation in reported dose by assessing a gold standard plan on individual contours [101]
and other studies have investigated other dosimetric aspects of contouring uncertainty in
the gynaecological context [101, 151–154].
4.4.1 Inter-observer Variation Analysis
As can be seen from Figure 4.2, there is variability between plans, patients and what
gold standard contour is used to assess the dosimetric variation. This is in contrast to
Hellebust et al who determined using a different methodology that the difference in
variability in rSD between gold standards is negligible [101]. Using the STAPLE
contour for dosimetric assessment of the CTVHR D90 generally results in slightly lower
mean doses and higher variation (rSD) within a single patient than using the EC contour.
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The same is true for most target contour parameters as can be seen in Table A.3. This
can be explained by the geometry and position of the contours. The STAPLE contour is
inherently similar to the observers contours on which each plan is optimised to, because
it is derived from these contours. Therefore similar doses may be expected. The EC in
this cohort is independent of each of the observer contours, and generally smaller in the
lateral and anterior/posterior directions than the STAPLE, hence the observed increase in
dose. Furthermore, since the EC lies within the STAPLE volume in these dimensions,
dose distributions optimised to a STAPLE-like contour will result in less variability in
D90 for the EC.
Depending on the dosimetric parameter chosen, substantial variability over the course of
the multi-modality treatment is observed. For CTVHR D90, STAPLE contours resulted
in 3.4 Gy EQD210 (8.1% rSD) variability. EC contours had smaller variability in CTVHR
D90, at 2.9 Gy EQD210 (6.1% rSD). The OAR variability was 1.2-3.6 Gy EQD23 for
D2cm3. These values are reported for the entire brachytherapy treatment. The single
fraction variability as presented in Table A.3, is 6.0% and 4.5% for the STAPLE and
EC CTVHR D90 respectively. Single fraction variability for the OARs ranges between
4.4-7.7%.
The dosimetric differences of these results and that of Hellebust et al [101], despite using
the same contours and applicator reconstructions, can be explained by different plan
optimisations methods as seen in Figure 4.1. In the current study, the dosimetry for each
observer is constrained by the ability to conform dose to each contour. In the previous
study, a single ’gold standard’ plan was prescribed to all contour sets. Hence, the
dosimetry varies amongst observers due to deviation in each observer contour relative to
the gold standard contour. The two approaches can therefore have substantially different
results despite utilising the same dataset, specifically resulting in a lower SD in CTVHR
for this study than Hellebust et al [101]. In addition the present analysis includes
intra-observer variations for the planning process itself however this has been minimised
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by using the same planner for all 71 plans. These methodology differences also explain
why in the present study, the rSD in Rectum D2cm3 is higher than the rSD in Sigmoid
D2cm3; but the opposite is true for Hellebust et al [101].
Tanderup et al identified that target contouring uncertainties (9%) account for almost the
entire intra- and inter-fraction uncertainty budget, however this is referring to the
variability in reported dose due to contouring uncertainties as determined in Hellebust et
al [101, 151]. The variability in prescribed dose due to planning variations as determined
in the current study (4.5-6.0%) was not included in this budget. Despite the inability to
linearly add these uncertainties, the prominence of contouring uncertainties in the HDR
cervix intra-cavity IGABT uncertainty budget is further reiterated. In the case of OARs,
reported contouring uncertainties (5-11%) make up a smaller fraction of the overall
20-25% inter-intra-fraction changes uncertainty budget [151]. The current study reports
the variability in prescribed dose due to planning variations as 4.4-7.7%, increasing the
proportion of the inter- and intra-fraction changes budget that is due to contouring
uncertainties. Organ motion remains a substantial component of the intra- inter-fraction
changes uncertainty budget, more so than for target contours [155].
4.4.2 Correlation Analysis
Overall, Tables 4.5, A.4 and A.5 imply that the smaller the CTVHR and CTVIR, the
larger the dose, with a decrease in the lateral, anterior/posterior and superior/inferior
directions correlating most with an increase in the dosimetric parameters investigated.
Adding a margin to account for these dosimetric variations due to differences in contour
dimensions may be considered, however since the application of margin in any direction
but the superior/inferior direction is not appropriate [156], the expansion should be
limited to these directions.
It is important to note that although significant correlations were found in this study, no
strong correlations (ρ > |0.7|) were observed. Most results indicated weak to moderate
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correlations (ρ > |0.3|, (ρ < |0.69|) as indicated by the ρ value in Tables 4.5, A.4 and
A.5.
4.5 Conclusion
There are differences in dosimetric outcomes arising from inter-observer variation in
target delineation for cervical brachytherapy, resulting in approximately 2.9-3.4 Gy
EQD210 variability in the CTVHR D90 over the course of the treatment, depending on
which gold standard contour is assessed. The maximum geometric dimensions of these
delineations were most commonly correlated with dosimetry changes. Although the
parameters that are significantly correlated are similar across gold standards, the
direction of these correlations differ, indicating that the dosimetric outcomes are
dependent on the contour that the plan is optimised to. This study reiterates the
importance of carefully choosing a gold standard from which to benchmark, and
highlights the potentially substantial dosimetric differences inter-observer uncertainty
can have.
Chapter 5
Validation of Dose Planning Variations
Related to Delineation Uncertainties in
MRI-Guided Brachytherapy for Locally
Advanced Cervical Cancer for the
Australian Context
This chapter validates the dosimetric variation arising from inter-observer variation
found in Chapter 4 on an Australian dataset, given the differences in brachytherapy
practice between Australian and European centres. Spatially descriptive contouring
metrics are quantified and compared to dosimetric metrics to determine whether
correlations exist. The findings in this chapter contribute to answering the first aim of
this thesis: to understand the impact of delineation uncertainty on radiotherapy efficacy
(Chapter 1.1).
The content in this chapter is in preparation for publication. The candidate’s contribution to this publication
is in the form of data generation, collection and analysis as well as authorship of manuscript.
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5.1 Introduction
Sources of uncertainty in brachytherapy are numerous, including source specification,
treatment planning, dose delivery and inter/intra-fraction changes [151]. By far the
biggest contributor to the total dosimetric uncertainty is the uncertainty in target
delineation (contouring uncertainties) [101, 151]. Despite adherence to protocols, there
is dosimetric variability due to contouring uncertainty, both in reported doses and
prescribed doses arising due to resulting planning variations. Our previous work,
presented in Chapter 4 investigated the variability in prescribed doses due to planning
variations from contouring uncertainties. The study was conducted on a GEC-ESTRO
dataset comprising European patient images and contours. The study found that
inter-observer variation in CTVHR definition produces substantial dosimetric variability,
up to 3 Gy EQD210 for an HDR image guided adaptive brachytherapy course for the
cervix. Additionally, correlations between commonly used delineation uncertainty
metrics and dosimetric outcomes were found to exist, linking increased dose with
smaller cardinal dimensions.
The current study aims to validate these findings in the Australian context. The validation
of the GEC-ESTRO findings with Australian data will negate the impact of small practice
differences and geographic-specific patient characteristics on dosimetric variations due to
contouring. This means that solutions to mitigate these effects can be applied universally,
despite local practice and patient demographic differences.
5.2 Methods
T2-weighted MRI from eight cervical cancer patients collected for the study (presented in
Chapter 3) were utilised [157]. The CTVHR was contoured by 12 independent observers
from Australian institutions practicing MRI-based cervical cancer brachytherapy. Two
gold standard contours were generated so that comparisons between observers can be
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made on an expert consensus CTVHR generated by a group of local experts in cervical
cancer contouring and the STAPLE [42]. OARs were generated by a single observer for
planning purposes.
Intra-cavitary (tandem and ovoid) brachytherapy plans were optimised according to local
clinical practice. Virtual treatments for these patients consisted of 45 Gy in 25 fractions of
external beam radiotherapy and 3 fractions of HDR brachytherapy [158]. Planning aims
and limits for prescribed doses for each fraction are presented in Table 5.1.
Table 5.1: Planning aims and limits for prescribed dose for a single fraction of IGABT
for cervix cancer.
D90 CTVHR D2cm3 Bladder D2cm3 Sigmoid D2cm3 Rectum
Planning Aims > 8 Gy < 5.8 Gy < 5.3 Gy
Limits for
Prescribed Dose < 6.5 Gy < 5.9 Gy < 5.9 Gy
The contouring variability in these contours was assessed via a number of metrics
including the location of the COM relative to the gold standards, the CI with respect to
the gold standards, the dimensions in the cardinal directions (MD-X, MD-Y, MD-Z) and
the volume. The variability in the dose achieved for the CTVHR for these plans was
assessed by comparing the mean, SD and rSD. The correlation between the dosimetric
metrics and contouring metrics was determined using a non-parametric Spearman’s rank
correlation.
5.3 Results
5.3.1 Planning
Table A.6 presents the reported doses for each optimised plan. 43/112 (38.4%) plans
failed to achieve the single fraction planning aim of > 8 Gy to CTVHR. For one patient
(patient 6), very little dose could be delivered to the CTVHR without exceeding OAR
limits due to unfavourable anatomy, with the STAPLE and EC CTVHR receiving 0.9 Gy
and 1.1 Gy respectively. It is acknowledged that this would not be used clinically. For
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the OARs, bladder planning aims were exceeded in 94/112 (83.9%) of plans. Rectum and
sigmoid colon planning aims were exceeded in 18/112 (16.1%) and 19/112 (17.0%) plans
respectively.
5.3.2 Contouring Variability
Table 5.2 shows the contouring variability metrics for the observer contours and gold
standards. The location of the x, y and z position of the COM relative to the gold
standards, averaging across all observers and all patients, varied 0.16 cm, 0.27 cm and
0.87 cm respectively. The maximum dimensions demonstrated a variation ranging
between 0.75 - 1.82 cm and a mean volume variation of 28.5 cm3 was observed. The CI
variation relative to the gold standards varied by 0.2 for both EC and STAPLE
contours.
5.3.3 Dosimetric Variability
The dosimetric variability for the gold standard contours (EC or STAPLE) arising from
plan optimisations based on different observers contours can be seen in Table 5.4. The
rSD in STAPLE CTVHR D90 across patients ranged between 3.20 - 11.77% and for the
EC CTVHR D90, ranged between 1.66 - 12.34%. The rSD represents the dosimetric
variability of the brachytherapy component of the treatment course only. The magnitude
in dosimetric variability is similar between gold standards. The EC exhibited greater
mean doses than the STAPLE, however a similar variability in prescribed dose is
observed.
CHAPTER 5. VALIDATION OF DOSE VARIATIONS 67
Table 5.2: Contouring variability metrics.
Patient 1 2 3 4 5 6 7 8 Mean
xCOM Mean (cm) -0.03 0.02 -0.14 0.02 0.09 0.15 0.00 0.09 0.02
STAPLE SD (cm) 0.16 0.08 0.17 0.10 0.21 0.40 0.05 0.11 0.16
xCOM Mean (cm) 0.16 0.00 0.17 0.06 -0.09 -0.58 0.02 -0.07 -0.04
EC SD (cm) 0.16 0.08 0.17 0.10 0.21 0.40 0.05 0.11 0.16
yCOM Mean (cm) -0.01 -0.12 -0.09 0.03 0.03 -0.50 0.02 0.00 -0.08
STAPLE SD (cm) 0.08 0.16 0.12 0.15 0.18 1.40 0.04 0.04 0.27
yCOM Mean (cm) 0.00 0.17 0.19 -0.20 -0.22 -1.46 -0.03 0.00 -0.19
EC SD (cm) 0.08 0.16 0.12 0.15 0.18 1.40 0.04 0.04 0.27
zCOM Mean (cm) 0.16 0.40 1.35 0.12 0.06 -1.18 0.09 0.17 0.14
STAPLE SD (cm) 0.39 0.79 1.19 0.63 0.41 2.94 0.26 0.37 0.87
zCOM Mean (cm) -0.03 0.18 -0.99 -0.45 -0.21 -1.95 0.16 -0.20 -0.44
EC SD (cm) 0.39 0.79 1.19 0.63 0.41 2.94 0.26 0.37 0.87
∆ COM Mean 0.34 0.61 1.55 0.48 0.38 2.8 0.22 0.37 0.84
STAPLE SD 0.30 0.66 0.93 0.44 0.33 2.02 0.17 0.21 0.63
∆ COM Mean (cm) 0.33 0.58 1.20 0.59 0.47 3.03 0.26 0.33 0.85
EC SD (cm) 0.30 0.60 1.02 0.56 0.34 2.76 0.18 0.29 0.76
MD-X Mean (cm) 5.30 6.16 5.91 5.12 4.95 7.41 4.18 4.95 5.50SD (cm) 0.63 2.22 1.29 0.35 1.05 2.38 0.51 0.68 1.14
MD-Y Mean (cm) 4.25 4.64 4.41 4.89 4.65 7.16 2.84 3.48 4.54SD (cm) 0.51 1.40 0.29 0.70 0.52 1.73 0.47 0.38 0.75
MD-Z Mean (cm) 3.77 5.51 5.44 5.44 4.36 7.14 3.16 4.19 4.88SD (cm) 0.88 1.82 2.86 2.86 1.21 2.87 0.80 1.25 1.82
Volume Mean (cc) 35.95 51.36 56.74 56.74 38.14 138.83 15.84 30.33 52.99SD (cc) 13.44 18.83 39.31 39.31 17.63 86.03 4.42 9.04 28.50
CI Mean 0.66 0.57 0.42 0.42 0.6 0.38 0.62 0.69 0.55
STAPLE SD 0.13 0.22 0.28 0.28 0.18 0.27 0.16 0.12 0.20
CI EC Mean 0.65 0.53 0.35 0.35 0.58 0.37 0.65 0.69 0.52SD 0.16 0.18 0.23 0.23 0.19 0.32 0.14 0.14 0.20
Table 5.3: Spearmans non-parametric rank correlation coefficient and significance. Statistically significant results shown in bold italics.
x COM y COM z COM C COM MD-X MD-Y MD-Z Vol Vol
ρ sig. ρ sig. ρ sig. ρ sig. ρ sig. ρ sig. ρ sig. ρ sig. ρ sig.
EC D90 0.48 < 0.01 -0.04 0.65 0.06 0.52 -0.28 < 0.01 -0.22 0.02 -0.15 0.12 -0.38 < 0.01 -0.31 < 0.01 0.18 0.05
EC D98 0.46 < 0.01 -0.06 0.55 0.09 0.33 -0.30 < 0.01 -0.25 0.01 -0.20 0.04 -0.39 < 0.01 -0.35 < 0.01 0.20 0.03
STAPLE
D90 0.01 0.9 0.17 0.08 -0.17 0.07 -0.58 < 0.01 -0.34 < 0.01 -0.55 < 0.01 -0.45 < 0.01 -0.48 < 0.01 0.44 < 0.01
STAPLE
D98 0.01 0.94 0.17 0.08 -0.17 0.08 -0.59 < 0.01 -0.34 < 0.01 -0.55 < 0.01 -0.45 < 0.01 -0.48 < 0.01 0.44 < 0.01
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5.3.4 Correlations
Table 5.3 shows the Spearmans non parametric rank correlation coefficient and
significance between the dosimetric and contouring parameters of the CTVHR.
A linear regression analysis testing for interaction was used to determine whether
correlations observed within the GEC-ESTRO dataset and the Australian dataset were
statistically the same. Table 5.5 presents the results where significance greater than 0.05
for the linear regression indicates that the Spearman rank correlations are statistically the
same between datasets.
5.4 Discussion
As contouring and treatment protocols for IGABT converge worldwide, there remains
local practice differences that distinguish European and Australian clinical practice. The
analysis of the GEC-ESTRO dataset found that inter-observer variation in CTVHR
definition produced up to 3 Gy EQD210 substantial dosimetric variability and that
increased dose to the CTVHR correlates with smaller cardinal dimensions. This study
investigated the planning variation due to inter-observer variation in the Australian
cohort and validated the findings from the GEC-ESTRO dataset on this cohort.
5.4.1 Similarities and Differences between Cohorts
The similarities and differences between the Australian and GEC-ESTRO cohorts are
summarised in Table 5.6.
The Australian dataset does not utilise interstitial needles, therefore the ability to conform
dose to individual tumour volumes is limited. This is most likely the main reason for the
substantially lower prescribed doses achieved in this study compared to the study utilising
the GEC-ESTRO interstitial brachytherapy dataset A.6. Other dataset differences include
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Table 5.4: Dosimetric variability in EQD2 averaged across all observers for each patient.
rSD is for the brachytherapy component only.
Patient 1 2 3 4 5 6 7 8 Mean
CTVHR D90
STAPLE
Mean (Gy) 84.20 59.92 51.40 68.88 62.73 46.61 77.52 72.39 65.46
SD (Gy) 4.70 0.51 0.56 0.95 0.88 0.21 2.39 0.90 1.39
rSD (%) 11.77 3.24 7.77 3.85 4.75 8.83 7.17 3.20 6.32
CTVHR D90
EC
Mean (Gy) 97.28 66.63 81.28 86.57 84.38 47.13 84.67 75.37 77.92
SD (Gy) 6.54 0.37 2.85 1.53 1.60 0.23 2.98 0.88 2.12
rSD (%) 12.34 1.66 7.70 3.61 4.00 7.87 7.36 2.83 5.92
CTVHR D98
STAPLE
Mean (Gy) 75.18 54.75 49.58 60.61 56.12 46.15 71.20 66.07 59.96
SD (Gy) 3.31 0.36 0.39 0.71 0.51 0.18 2.01 0.73 1.02
rSD (%) 10.69 3.47 7.29 4.34 4.27 9.28 7.47 3.36 6.27
CTVHR D90
EC
Mean (Gy) 83.96 60.05 72.15 76.9 75.23 46.44 77.18 67.93 69.98
SD (Gy) 4.34 0.31 2.07 1.19 1.23 0.16 2.50 0.78 1.57
rSD (%) 10.92 1.96 7.41 3.63 3.98 7.53 7.59 3.28 5.79
Bladder
D2cm3
Mean (Gy) 67.95 80.10 75.35 79.65 79.68 79.68 76.92 80.13 77.43
SD (Gy) 2.63 0.21 2.41 0.68 1.63 1.65 3.11 0.10 1.55
rSD (%) 10.63 0.57 7.48 1.86 4.47 4.54 9.22 0.26 4.88
Sigmoid
D2cm3
Mean (Gy) 63.51 45.07 51.20 69.20 58.4 - 58.03 73.65 59.86
SD (Gy) 2.46 0.07 0.64 0.49 1.36 - 1.21 1.12 1.05
rSD (%) 12.11 3.64 7.98 1.87 8.96 - 8.16 3.67 6.63
Rectum
D2cm3
Mean (Gy) 59.54 65.78 64.77 61.17 55.71 72.12 69.46 60.37 63.62
SD (Gy) 1.69 2.41 2.93 0.73 2.36 2.46 3.20 2.48 2.28
rSD (%) 10.35 10.68 13.59 4.05 18.85 8.49 12.19 14.43 11.58
Table 5.5: Linear regression analysis results for significant correlations in the GEC-
ESTRO study [64] and this study. Statistically significant results shown in bold italics.
GEC-ESTRO Spearman
Rank Correlation
Australian Spearman
Rank Correlation Regression Analysis
STAPLE ρ (sig) ρ (sig) ρ (sig)
MD-X and D98 -0.27 (0.02) -0.34 (< 0.01) 1.29 (0.37)
MD-Y and D98 -0.34 (< 0.01) -0.55 (< 0.01) 2.35 (0.13)
MD-Y and D90 -0.27 (0.02) -0.55 (< 0.01) 4.37 (0.02)
Vol and D98 -0.25 (0.04) -0.48 (< 0.01) 0.06 (0.32)
EC (sig) (sig) B (sig)
MD-X and D98 -0.38 (< 0.01) -0.25 (0.01) 2.33 (0.13)
MD-Y and D98 -0.39 (< 0.01) -0.20 (0.04) 3.84 (0.03)
MD-Z and D98 -0.25 (0.04) -0.39 (< 0.01) 2.64 (0.04)
Vol and D98 -0.32 (0.01) -0.35 (< 0.01) 0.11 (0.05)
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Table 5.6: Similarities and differences between Australian and GEC-ESTRO IGABT
cohorts.
GEC-ESTRO Dataset [64] Australian Dataset [157]
Interstitial cervix IGABT Intra-cavity cervix IGABT
Tandem and ring Tandem and Ovoids
6 patients, 10 observers 8 patients, 12 observers
European contourers who have
participated in EMBRACE II
Australian contourers adhering to
local protocols.
CTVHR, CTVIR, GTV and OARs
contoured by each observer
CTVHR contoured by each observer. CTVIR,
GTV and OARs contoured by local radiation therapist
EC determined by multiple experts (> 3)
through Europe, of different disciplines EC determined by 3 radiation oncologists at one institution
7.2Gy in 4 fractions 8 Gy in 3 fractions
the use of ovoids in this current study as opposed to a ring. There is a similar presence of
inter-observer variation across datasets however the types of contours generated differed.
Specifically, the Australian dataset lacks multiple observer contours for OARs, as well as
contours for the other target volumes recommended by the EMBRACE study (CTVIR and
GTV). The EC contour was determined from three Australian radiation oncologists from
the same institution as opposed to the multi-discipline and multi-institutional approach
in defining the EC contour for the GEC-ESTRO cohort. Although the planning aims are
similar between studies, they are not identical and the fractionation schemes are different,
with this dataset planned based on a virtual treatment of 8 Gy in 3 fractions as opposed to
7.2 Gy in 4 fractions. It is important to note that the same physicist generated the plans in
both studies, negating the inter-planner variations.
5.4.2 Inter-observer Variation Analysis
Patients in which CTVHR D90 planning aims were frequently met (patients 1, 3 and 7)
exhibited greater dosimetric variability. This is due to favourable OAR positioning
relative to the target contours, enabling greater flexibility and feasibility of dose
escalation. For cases where the OARs were positioned close to the target volume, a
smaller dosimetric variability was observed amongst inter-observer plans since further
CHAPTER 5. VALIDATION OF DOSE VARIATIONS 72
dose optimisation is limited by OAR tolerances.
It is clear that the gold standard on which the plans are evaluated has an impact on the
mean dose reported, specifically, plans assessed on the EC result in larger doses than those
on the STAPLE. However, the amount of variability in prescribed dose is similar between
gold standards. Over a full treatment course, the inter-observer variation in CTVHR D90
results in 1.4 Gy EQD210 (6.3% rSD) variability in prescribed dose for the STAPLE
contour, and 2.1 Gy EQD210 (5.9%) for the EC. This is similar, though slightly smaller
variability than observed for the GEC-ESTRO cohort (3.4 Gy for the STAPLE and 2.9 Gy
for the EC). The differences are likely due to the limited flexibility in dose optimisation
for the Australian cohort, due to the lack of interstitial needles.
5.4.3 Correlations
Common types and magnitudes of correlations were found for the investigated dosimetric
parameters (D90 and D98) between the Australian and GEC-ESTRO cohorts. Significant
correlations of increased dose were observed in both cohorts for decreasing maximum
dimensions and volume. In both cohorts, as a contour decreases in the cardinal directions
and decreases in volume, greater dose was achieved. This was observed for both gold
standards. The Australian cohort was also shown to correlate dose with decreased COM
displacement and increased CI, however this was not observed in the GEC-ESTRO cohort.
This implies that the Australian dataset is more sensitive to the dosimetric impact of inter-
observer variation than the GEC-ESTRO dataset, in that any deviation from the ’true’
volume showed a correlated decrease in achievable dose.
The observed correlations between maximum lateral dimensions and dose to 98% of the
target volume, as well as volume and dose to 98% of the target were statistically the same
between datasets for both gold standards. When using the STAPLE as a gold standard,
the correlation between maximum anterior/posterior dimensions and dose to 98% of the
target volume were verified to be the same in both datasets. This shows that these findings
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are robust across different treatment modalities, contourers, treatment practices and other
differences between datasets outlined in Table 5.6.
5.5 Conclusion
Despite numerous differences in treatment technique, fractionation schedule and
geographical location of the datasets (which inherently include differences in training,
clinical practice and patient demographics), the findings of the GEC-ESTRO dataset
have been validated in the Australian cohort. Similar dosimetric variability is observed
across an equi-effective treatment course, despite differences in prescribed dose.
Correlations between increased dose and target contractions in the cardinal dimensions
were observed. One distinction observed was the correlation between dose and COM
location and CI observed in the Australian dataset, but not the GEC-ESTRO dataset.
This indicates a greater dosimetric sensitivity to inter-observer variation. The validation
of the GEC-ESTRO findings means that methods to mitigate the effects of inter-observer
variation in the cervix IGABT context, such as a delineation margin, can be universally
applied.
Chapter 6
Atlas-Based Segmentation Technique
Incorporating Inter-Observer
Delineation Uncertainty for Whole
Breast
This chapter investigates an atlas-based auto-segmentation method for whole breast
radiotherapy. This method improves on the accuracy of existing techniques by
incorporating inter-observer variation into the segmentation process. The findings of this
chapter contribute to answering the second aim of this thesis: to minimise delineation
uncertainty by automating the contouring process (Chapter 1.1).
The content in this chapter has been published. The candidate’s contribution to this publication is in the
form of data generation, collection and analysis as well as manuscript authorship.
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6.1 Introduction
Internal anatomical changes during the course of radiotherapy limit treatment accuracy,
as current treatments are planned on static images obtained prior to delivery. Adaptive
radiotherapy is an increasingly investigated approach that aims to combat these
anatomical changes by re-imaging and re-planning at multiple time points throughout
the treatment course. However, this process has large workflow implications due to the
time required to achieve this whilst maintaining plan quality.
Target delineation is the bottleneck of the planning process taking on average 18.6 min
per patient for breast radiotherapy [69], and housing one of the largest uncertainties
affecting modern radiotherapy accuracy [3, 159]. Segmentation techniques, boasting
significant decreases in delineation times as compared to manual contouring, have been
proposed as the solution to this limitation with several techniques implemented with
impressive results [160, 161]. Atlas-based segmentation techniques in particular are
suited for adaptive radiotherapy purposes as they are derived from real patient anatomy
and verified clinician contours. However, current techniques generally fail to incorporate
inter-observer variation, with single clinician contours frequently taken to be the gold
standard delineation. With the largest uncertainty in modern radiotherapy treatment
occurring during the target delineation process, it is essential to account for delineation
uncertainty when devising an adaptive radiotherapy process.
This atlas-based segmentation technique improves on the accuracy of existing techniques
by incorporating inter-observer variation into the segmentation process, whilst
maintaining efficacy.
6.2 Methods
This segmentation technique, although developed and validated for a whole breast, is
applicable to any target volume definition in which the contours are defined based on
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Figure 6.1: Method for atlas generation.
anatomy. The general process involves generating atlas, registering the atlas to a new
patient to obtain good correspondence between equivalent regions, and mapping the atlas
segmentation to the new image space.
6.2.1 Technique Development
The atlas generation method, outlined in Figure 6.1, has been utilised previously in
medical imaging applications [162, 163]. An initial dataset representative of the patient
cohort was chosen with remaining datasets in the cohort registered to the initial dataset
using rigid and affine transformation [164]. The results were averaged and used as the
subject for the next iteration in which rigid, affine registration and diffeomorphic demons
non-rigid registration [165] was used. Three iterations were performed to produce the
final atlas.
All CTVs except those of the left-out dataset were mapped to atlas space using the
existing deformation fields and merged. The resulting contouring probability model was
thresholded to 50% to obtain an auto-segmented CTV contour.
6.2.2 Validation
The technique was validated on a whole breast radiotherapy cohort containing datasets
from 28 patients (14 right, 14 left), collected for a previous study [22]. Non-contrast
CT scans were used with whole breast CTV delineated by eight independent observers.
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Figure 6.2: Distribution of patient cohort within volume categories.
Observers followed a delineation protocol and were blind to other observer contours [22,
37].
Since atlas accuracy correlates with similar anatomy of input patients [166], the cohort
was divided into categories, grouping similar patients. Body mass index (BMI) was used
as a surrogate for similar patient anatomy, with small/large patients classed as </> 29
BMI and datasets were further divided according to laterality. Figure 6.2 shows the
distribution of patient datasets.
An atlas was generated from the 6-9 datasets in each category using the MILXView
platform [162] using a leave-one-out approach. The atlas was registered using rigid,
affine transformation followed by non-rigid registration to the ’left out’ dataset as shown
in Figure 6.3. The auto segmentation was mapped to this dataset from atlas space, and
clipped such that it did not extend past the patient surface.
A gold standard, consensus contour was generated from the observer CTVs on the left-
out dataset in each category using the STAPLE algorithm [42] in MILXView. To assess
similarity, the gold standard contour was compared to the auto-segmentation using the
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Figure 6.3: Applying the auto-segmentation method to a new patient.
DSC [167] and MASD [168]. A comparison between the smallest and largest CTV with
the auto-segmentation was also made to determine the range in accuracy.
6.3 Results
Average atlas’ with corresponding whole breast CTV segmentations were successfully
generated for each category.
The average atlas for each category with corresponding probability maps is shown in
Figure 6.4. The whole breast CTV auto-segmentation is visually compared to the
consensus, smallest and largest contour in Figure 6.5. The time required to
auto-segment, including registration of the atlas to the required patient and propagating
contours, was on average 3 min and 43 seconds. The DSC and MASD values indicating
the accuracy of the auto-segmentation in delineating the whole breast CTV and
accounting for inter-observer variation is shown in Table 6.1.
The regions of largest deviation between the auto-segmentation and consensus volume is
visually seen in Figure 6.6 medially in the small BMI category, and at superior/inferior
slices for the large BMI category.
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Figure 6.4: Probability maps of observer contours for a) large right, b) large left, c)
small left and d) small right atlas’. Heat map indicates regions of highest probability.
Figure 6.5: Auto-segmentation (yellow colour wash) for left-out patients. A) large right,
b) large left, c) small left and d) small right categories. STAPLE (green), smallest (blue)
and largest (red) CTVs are shown for comparison.
Table 6.1: Similarity metrics comparing whole breast segmentation with manual target volumes.
DSC MASD (mm)
Large Left Large Right Small Left Small Right Large Left Large Right Small Left Small Right
Consensus 0.81 0.85 0.71 0.79 7.99 3.47 6.17 5.16
Smallest CTV 0.77 0.86 0.71 0.79 9.28 3.64 4.81 5.16
Largest CTV 0.81 0.80 0.71 0.79 7.50 4.71 6.13 5.07
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Figure 6.6: Differences in whole breast auto-segmentation (blue) and gold standard
contour (red) for large BMI patients (right) and small BMI (left) in the coronal plane.
Common regions are shown in pink.
6.4 Discussion
Coverage probability maps overlaid on average atlas’ showed high observer agreement
for the majority of the whole breast segmentation. Observer agreement was lowest in the
anterior-medial and posterior-lateral directions as is supported in literature [69,
169].
Auto-segmented contours generally compared well with the gold standard for each
category. Insufficiencies in auto-segmentation were observed close to the chest wall for
large and small BMI left breast patients. The authors hypothesise that this is due to
larger segmentation variations amongst observers and patients due to the close proximity
of the heart. Manual review by of this key area by a clinician is recommended.
Improvements in segmentation in these instances could be achieved through optimisation
of the probability map thresholding value.
Nevertheless, auto-segmentation accuracy was high, producing high concordance (DSC
> 0.7) with target volumes in all volume categories. Although MASDs were often
greater than 5mm, which is the tolerance quoted in Chapter 3, they were limited to less
than 1 cm with location of largest surface differences specific to BMI category. For the
purposes of this study, this is deemed acceptable due the the unique PTV shape of whole
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breast volumes, where distances between contours can be large in the anterior/medial
and posterior/lateral regions, despite being qualitatively similar. The largest differences
for large BMI patients occurred in the medial direction and for small BMI patients in the
superior direction.
6.5 Conclusion
This atlas based auto-segmentation technique incorporating inter-observer variation has
been shown to be accurate (DSC < 0.7) and efficient (time < 5 min) as is necessary for
the clinical efficacy of adaptive radiotherapy. There is scope for further optimisation of
correlation with gold standard segmentations as well as computation time. This method
is a feasible solution to auto-segmentation adaptive radiotherapy with the potential for
viable application to other anatomical sites.
Chapter 7
A Comparison of Coordinate Systems
for Use in Determining a Radiotherapy
Delineation Margin for Whole Breast
This chapter investigates the most appropriate coordinate system to define a whole breast
radiotherapy delineation uncertainty margin, given that a conventional three-plane
cartesian margin may not adequately account for delineation uncertainty. The findings of
this chapter contribute to answering the third aim of this thesis: to manage delineation
uncertainty using an uncertainty margin (Chapter 1.1).
7.1 Introduction
Radiotherapy treatment techniques have improved significantly with the implementation
of IMRT, VMAT and image-guided radiotherapy. Further improvements in radiotherapy
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are achieved by setting clear delineation protocols, minimising set-up errors and imaging
errors, and imaging for internal motion management [6]. Delineation uncertainty arising
from inter-observer variability has traditionally been ignored as larger systematic errors
dominate. Inter-observer variability is still a significant uncertainty, even with clear
delineation protocols and uncertainties from delineation, may now play a significant role
in influencing the success of these improved techniques.
Although the inclusion of delineation margins in PTV margin recipes is well
acknowledged in the literature as necessary, particularly with the introduction of more
conformal delivery techniques calculation of these margins is rarely attempted. Studies
have been performed for cancer sites such as the prostate [14, 170] and the brain [171] to
optimise set-up and motion margins ignoring the inter-observer delineation uncertainties.
These have shown that margins are necessary to reduce the likelihood of geographical
misses, reduce effects from systematic errors (under-dosage) and reduce effects from
random errors (blurring) [6]. Margin formulae using the combined
preparation/systematic standard deviation (Σ) and execution/random standard deviation
(σ ) such as 2.5Σ+0.7σ−3 mm [10], incorporate inter-observer variability within the
preparation errors (Σ). However this is performed with one value over the whole
structure equally or with 3 values in 3 planes. As the inter-observer variation may be
accurately determined over the whole structure (multiple angles and points), perhaps this
adaptation should be performed before the other margin formula is applied. The
appropriate amount or weight that this should have compared to the whole margin
formula needs to be investigated further.
Introduction of an additional margin, or ensuring PTV margins include the inter-observer
variability margin, to account for breast delineation uncertainties would reduce the
clinical impact of inter- and intra- observer variation. This has previously been
performed using cartesian coordinates for sites such as the prostate and seminal vesicles
[172], partial breast [173], whole breast [174] and performed using spherical coordinates
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for sites such prostate [38] and bladder [125]. Shape of the target will play a significant
role in what coordinate system should be used.
7.2 Methods
Datasets from 9 patients from a previous study were utilised [22]. Volumes of the CTV
were contoured by four breast cancer radiation oncologists (with experience ranging
from 6 to over 20 years in oncology) and four radiation therapists (with experience
ranging from 3 to 13 years). One-sided whole breast CTV were outlined on transverse
slices with a standard window level (0) and width (500). Radio-opaque wire was used to
aid delineation. Each observer was allocated a unique letter to de-identify their contours.
Observers were blind to other observer contours. The SD in delineation uncertainty
using cylindrical coordinates for 360 degrees in 1 degree increments and in cartesian
coordinates (the maximum in each X and Y direction) for whole breast was compared.
As the CTV structure may be easily elongated many papers calculate the deviation in the
cardinal directions (from the geometric center coordinates in 6 directions) and perform
this adaption enabling some change over the entire volume. This has been generally
undertaken to account for tumour motion, however for inter-observer error a more
detailed expansion at many directions may be necessary. For this study 360 interpolated
points were calculated for each slice in cylindrical coordinates and compared to the
cartesian cardinal points and extensions. The interpolation at 1 degree increments were
compared with the original structures to ensure the shape of the structures remained
constant. The SD of this was calculated for slices as in Equation 7.1 for cylindrical
coordinates and Equation 7.4 for cartesian coordinates.
7.2.1 Cylindrical Coordinates
The contours were input into the Computational Environment for Radiotherapy Research
(CERR) software platform (v5.1) within the MATLAB environment as DICOM-RT
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structure sets and associated cartesian coordinates (X,Y,Z) were determined for each
patient and observer at the selected slices [147, 175]. The cartesian coordinates were
then converted into cylindrical coordinates for analysis. The SD of contour positions
were determined for cylindrical coordinates at θ = 1◦ increments for 5 slices (Z = -2 cm,
-1 cm, 0 cm, 1 cm and 2 cm from the origin) for each patient using equation 7.1, where
N is the total number of observers per patient and r¯ is the radius averaged over all
observations, Z is the slice or height of the structure in cm, j is the observer, i is the
patient number and θ is the cylindrical angle ranging from 0◦-360◦.
SD =∑ jinter−observer,radial(θ ,Z) =
√
∑Ni=1(r
j
i (θ ,Z)− r jobs(θ ,Z)2)
N−1 (7.1)
The mean COM was used as the origin for the right breast, for the left the COM was
shifted 1 cm superiorly to avoid clipping of the structure. If an observer did not have a
contour on a distal slice (e.g. Z = 2 cm) the number of observers was reduced to those
present. A margin to account for margin delineation uncertainty (MDU) was then
calculated as in equation 7.2 where SD is the standard deviation, i the patient number
and θ , Z indicates the direction. This is not recommended and is simply a preliminary
study into the validity of including inter-observer margins in multiple directions in PTV
margin recipes.
MDU iθ ,Z = 4×SDiθ ,Z (7.2)
This margin was selected such that 95% of the contoured union volume would be
included for any of the initial contours assuming a Gaussian distribution of contour
variation. The margin to be used on a new patient would be calculated using all 9
previous patient datasets as outlined in equation 7.3 where P is the total number of
patients.
CHAPTER 7. COORDINATE SYSTEMS FOR A DELINEATION MARGIN 87
MDUgeneralθ ,Z =
∑Pj=0 MDU iθ ,Z
P
(7.3)
7.2.2 Cartesian Coordinates
The SD and MDU were determined for cartesian coordinates for medial-lateral and
anterior-posterior positions, following previously published methodology [174]. If
inter-observer variability is considered in studies the SD is calculated usually in only 6
directions as treatment planning systems typically allow extension only in the anterior
(A), posterior (P), superior (S), inferior (I), lateral (L) and medial (M) directions by one
value for all points (from the average COM). The SD is outlined in equation 7.4 where
xd is the pixel position, in cm, at the edge of the contour in the appropriate direction (d =
A, P, S, I, M, or L); and xCOM is the average centre of mass coordinate also in that
direction (d).
SD =
√
∑Ni=1[(xi,d− xi,d,COM)− (xi,d− xi,COM)]2
N−1 (7.4)
The MDU is found as in equations 7.2 and 7.3, where d is the directions replacing and Z
(A, P, S, I, L or M). The MDU was added onto the observer contour in all 6 directions to
generate a CTV with a margin to account for inter-observer errors. For all methodologies
the MDU would be clipped to the skin, lung, heart, muscle interface and the medial border
if necessary.
7.3 Results
Figure 7.1 displays the interpolation points and original points of eight contours on one
patient at slice Z = 0 cm for cylindrical interpolation at 1 degree increments, indicating
consistency through the interpolation with minimal clipping or divergence.
Figure 7.1: (a) Interpolated data points in cylindrical coordinates for patient 1 at slice Z = 0 cm. The interpolated points are shown as crosses and
the original data is shown as solid lines. The same colour has been used for each observer. Parts (b) and (c) are expanded views of the structure
shown in (a).
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Figure 7.2: The contours at Z = 0 cm for patient 1, with the overall uncertainty for all
patients at Z = 0 cm overlaid in red.
The interpolation used linear interpolation at 1 degree increments. The overall uncertainty
for Z = 0 cm is plotted for patient 1 in Figure 7.2. Figure 7.2 highlights the anatomical
borders that are most affected by the uncertainty.
At slice Z = 0 cm considering cylindrical coordinates (lateral = 0◦), the SD peaked
medially reaching 3.55 cm at 15◦ for the right breast, and 1.44 cm at 171◦ for the left
(see Figure 7.3). The SD of the remaining slices maintained a similar distribution, with
variation in the peak occurring within 10◦ of the Z = 0 cm positions. In comparison, for
cartesian coordinates at slice Z = 0 cm, the largest SD in the medial-lateral and
anterior-posterior directions was 0.54/0.57 cm and 1.03/0.67cm respectively for right/left
breasts. The average MDU for the cardinal directions in cartesian coordinates is
displayed in Table 7.1 [174].
It can be seen in Figure 7.4 that for every contour, the additional margin of 4 SD is in line
Table 7.1: SD and MDU to account for delineation uncertainty in cartesian coordinates.
Direction Anterior Posterior Medial Lateral Superior Inferior
Right SD (cm) 0.40 0.22 1.15 1.48 0.52 0.79
Left SD (cm) 0.32 0.46 1.70 1.13 0.46 0.64
Left MDU (cm) 1.28 1.86 1.13 1.70 1.83 2.57
Right MDU (cm) 1.61 0.87 1.15 1.48 2.07 3.17
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Figure 7.3: The uncertainty (1SD) derived from 5 patients with right breast cancer (a)
and 4 with left breast cancer (b) utilising 8 observers calculated in cylindrical coordinates
for Z = -2 cm, -1 cm, 0 cm, 1 cm, 2 cm.
Figure 7.4: Patient 1 (right breast) contours are all within the minimum MDU calculated
from cylindrical coordinates. All 8 observers lie within the minimum observers contour
with the addition of the MDU. The thin lines are observers 1-7, observer 8 contour
(minimum contour) is the thick dark blue line. The light blue thick line is the MDU
of observer 8. Each observers contour is of a different colour consistent through all
slices.
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with the statistical account of 95% for any observers contour. This was also the case for
Z = -2 cm, -1 cm, 1 cm and 2 cm as shown in Figure 7.4 for patient 1. This is the case
for all the patients, only one patient is shown as an example for clarity. The mean SD was
calculated separately for left and right breast patients.
7.4 Conclusion
It has been shown that there is more accuracy in calculating a standard deviation at
multiple points (1 degree increments) to extend the CTV to account for inter-observer
error, rather than extending X, Y and Z by their cardinal variances. Margins are larger in
some directions using cylindrical coordinates than if the contour was extended by these
cardinal variances. This highlights the regions where inter-observer variation is high
such as both edges of the contours for both left and right breast patients. At slice Z = 0
cm considering cylindrical coordinates (lateral=0◦), the SD peaked medially reaching
3.55cm at 15◦ for the right breast, and 1.44cm at 171◦ for the left. The SD of the
remaining slices maintained a similar distribution, with variation in the peak occurring
within 10◦ of the Z = 0 cm positions. By comparison, for cartesian coordinates at Z = 0
cm, the largest SD in the medial-lateral and anterior-posterior directions was
0.54/0.57cm and 1.03/0.67cm respectively for right/left breasts. Future work will
calculate and compare cartesian coordinates at every point to cylindrical coordinate
calculations. Sensitivity to COM variations and a spherical coordinate analysis method
is also being investigated. Incorporation into a margin recipe that includes organ motion,
set-up errors and random errors should be investigated for clinical implementation. A
method of extending contours outside six directions (e.g. 360 directions) used in
treatment planning systems also requires investigation.
Chapter 8
Defining and Assessing an Anisotropic
Delineation Margin
This chapter defines and assesses an anisotropic delineation margin in both polar and
spherical coordinate systems in order to account for the spatially varying nature of this
uncertainty. A whole breast radiotherapy cohort was used as a proof of concept. The
findings of this chapter contribute to answering the third aim of this thesis: to manage
delineation uncertainty using an uncertainty margin (Chapter 1.1).
8.1 Introduction
Studies investigating margins to account for delineation uncertainty are few. One study
has investigated this concept, utilising contour coverage as a function of the applied
margin to determine an isotropic GTV to PTV delineation margin for non-small cell lung
cancer [159]. Another introduces the delineation margin concept on which this work is
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based, for whole breast radiotherapy in cartesian coordinates [174]. Work presented in
Chapter 7 compared coordinate systems for defining a whole breast radiotherapy
delineation margin at selected slices in polar and cartesian coordinates [169]. However, a
margin to account for delineation uncertainty may need to be anisotropically defined
outside the cardinal directions to account for the spatially varying nature of this
uncertainty [38, 125, 127, 128, 169]. Existing uncertainty margins vary only in the
cardinal directions, therefore the uncertainty in all directions may not be appropriately
accounted for.
This study investigates an anisotropic delineation margin applied to whole breast
radiotherapy as a proof of concept, utilising an available inter-observer variation cohort
[22]. This is the first study to determine and assess an anisotropic delineation margin that
accounts for the largest contouring uncertainties where they occur. For comparison with
current margin practices, this approach was compared to a conventional approach that
extends the whole breast CTV in the cardinal directions. Spherical and polar coordinates
were both used for the anisotropic approach, as either may be appropriate in describing
the whole breast CTV shape.
8.2 Methods
8.2.1 Margin Definition and Methodology
The MDU utilises the radial SD (Σ) in observer contours averaged across datasets. A
’leave-one-out’ approach is used in which the margin is determined for all datasets within
the cohort but the subject. Margins were defined to enable each dataset to be the subject.
The SD was then multiplied by a weighting factor (MDU = αΣav). This approach is an
adaptation of the first systematic term of existing margin recipes [9, 14], as delineation
uncertainty is systematically carried through all treatment fractions in current techniques.
The weighting factor was chosen to be α=2, as it is a commonly referenced and accepted
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coefficient for systematic uncertainties in published margin recipes. Furthermore, it is the
smallest published coefficient hence producing a conservative delineation margin and it
is representative of 95% confidence interval in which observer contours lie [9, 14]. The
expansion of a CTV at relevant points by the MDU results in a target volume that accounts
for delineation uncertainty (PTVdel).
The MDU aims to encompass all malignant cells (the true target volume), regardless of
which observer CTV it is applied to. This work has assumed that the true target volume
is somewhere between the smallest and largest observer contour. In assessing the tissue
missed by the MDU the conservative approach of assessing if the union volume of all
CTVs is encompassed when the MDU is added was taken. To account for the fact that this
will also include healthy tissue, the amount of included extra healthy tissue (determined
to be healthy, not CTV, by all observers) has also been assessed.
It is not apparent whether similar sized CTVs across datasets are required for derivation
of a satisfactory MDU. Hence, the utilisation of datasets with similar target volumes only
(a volume specific approach), as opposed to the whole cohort when defining a MDU was
compared to determine whether the margin method is dependent on similar anatomy. The
volume specific approach involved the patient cohort being divided according to small,
medium and large average CTV volume as well as right and left laterality, with MDUs
defined for each.
8.2.2 Implementation
As a proof of concept, datasets from 21 breast cancer patients (9 right, 12 left)
undergoing breast conservation surgery and adjuvant breast radiotherapy were utilised.
Approval was granted by the Sydney South West Human Research Ethics Committee.
This cohort is a subset of a tangential breast radiotherapy cohort collected for a previous
study, comparing radiation therapist and radiation oncologists volumes, utilising CT
datasets of identical slice thicknesses [22]. Each patient underwent a non-contrast CT
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scan with a 2.5 mm slice thickness in the supine position for the purposes of breast
radiotherapy. Eight independent observers from the same institution, including four
radiation oncologists and four radiation therapists, delineated the whole breast CTV
according to a delineation protocol adapted from Struikmans et al [22, 37] and were
blinded to other observer contours.
Image visualisation, data extraction and data manipulation was achieved using CERR
[147, 175]. To effectively use polar and spherical coordinate systems for an anisotropic
approach, the CT origin was shifted to the average COM of all observer CTVs on each
transverse slice, and in three dimensions respectively [176]. Data points describing each
CTV were similarly shifted and converted into both polar and spherical coordinates. The
nearest neighbour interpolation method was used to obtain radii at every whole angle for
comparison of corresponding CTV points across different observers and patients.
The SD for both anisotropic approaches in defining the MDU was determined in polar
and spherical coordinates. For polar coordinates, the SD in observer contours on each
transverse slice was determined radially according to Equation 7.1, where N is the total
number of observers per patient (N=8), j is the observer, i is the patient number, ri(θ ,Z)
is the radius of the contour at a particular theta (θ ) projection and z slice, robs(θ ,Z) is the
average radius of all observations at the same θ projection and Z slice [127].
The SD in observer contours for spherical coordinates was taken radially in
three-dimensions according to Equation 8.1 [125, 127, 176]. ri(θ ,φ) is the radius of the
contour at a particular 3D projection defined by θ and φ , robs(θ ,φ) is the average radius of
all observations at the same 3D projection.
SD =∑ jinter−observer,spherical(θ ,φ) =
√
∑Ni=1(r
j
i (θ ,φ)− r jobs(θ ,φ)2)
N−1 (8.1)
For a conventional margin definition approach, the SD in observer contours on each
transverse slice was determined using Equation 8.1 in the right, left, anterior, posterior,
CHAPTER 8. DEFINING A DELINEATION MARGIN 96
superior and inferior directions. To minimise the impact of outliers, SD were determined
at the three angles surrounding these directions (theta angles of 0◦, 90◦, 180◦ and 270◦
and phi angles of 0◦ and 180◦) and averaged to define the margin.
The gold standard (GS), consensus CTV for each patient was determined from all
observers using the STAPLE algorithm [42]. The STAPLE algorithm computes a
probabilistic estimation of the true segmentation based on the estimated performance
level of each input contour. This STAPLE volume is considered the gold standard
computed using probabilistic estimations of all 8 observers contours. Datasets were
assigned a volume category based on average CTV volume, and the calculated MDU for
that category was added to the GS volume in each dataset to generate the PTVdel, GS. The
MDU was additionally applied to the largest and smallest observer CTVs for a best case
PTVdel, smallest and worst case PTVdel, largest respectively.
The anisotropic margin was applied by adding the MDU to the radial magnitude of the
target volume at each angle. The conventional margin was applied by inputting the six
MDU magnitudes into the Pinnacle3 treatment planning system (v9.8) to expand the GS,
smallest and largest CTV volumes in the cardinal directions, as is current clinical practice
for CTV expansion. All PTVdel were clipped to the patient surface to provide a more
clinically relevant volume.
Polar and spherical coordinate systems require an origin to lie within the structure they
define. Since whole breast CTVs are approximately crescentric in shape, these
coordinate systems are not always suited for describing breast CTVs. A particular
angular projection may describe more than one point on the surface of a whole breast
CTV as seen in Figure 8.1. If the standard deviation is calculated between two points
describing different areas of the CTV surface, the resulting margin will not represent the
true inter-observer variation.
This effect occurs through-plane as well since whole breast CTVs are also crescentric in
the superior-inferior direction. To account for this, the SD was limited to half the
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Figure 8.1: Potential coordinate system failure on a transverse slice. A single projection
may intersect more than one point for each whole breast CTV. In the case that point 1 is
used, the SD between the solid and dotted contours along that projection will be large,
reflecting the separation of points 1 and 3. The true SD should be taken between points 3
and 4 since they lie at similar locations on the CTVs. This will affect margin calculations
with the margin size overestimated in regions where this occurs.
maximum Hausdorff distance [177] between CTVs, calculated pairwise using the
MILXView platform [162], as this is approximately similar to the true SD in observer
contours. The frequency of coordinate system failure was determined by finding the
number of times the MDU was limited. To determine the effect this coordinate system
failure has on the overall volume, the DSC [167] comparing the original structure and
the interpolated structure was determined.
8.2.3 Assessment
The MDU derived from all datasets in the cohort and the volume specific MDU derived
from the datasets in each volume category were statistically compared to justify the use
of volume categories. The approach that produced the most favourable results in terms of
accounting for contouring variation, whilst including minimal extra healthy tissue (extra-
included tissue, EIT) and including minimal malignant tissue (missed tissue, MT), was
used for the rest of the study. Statistical analysis was performed using a Wilcoxon Signed
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Figure 8.2: Example schematic outlining the components of MT and EIT resulting from
the delineation margin applied to a target volume. Potential EIT not depicted as this only
occurs when the coordinate system fails.
Rank test in IBM SPSS Statistics v21.0 with p < 0.05 significance [150].
The coverage of PTVdel with each original CTV (Equation 8.2) was determined to gauge
the robustness of the inter-observer uncertainty encompassment for different margin
approaches. Original CTVs were used instead of interpolated volumes to minimise
potential errors arising from coordinate system failures. Successful coverage exceeded
95% [11].
Coverage(%) =
PTVdel ∩CTVi
CTVi
×100 (8.2)
MT and EIT were defined for all datasets using Equations 8.3, 8.4, 8.5, see Figure
8.2.
Definite and potential components to EIT and MT were defined based on whether the
tissue lies within the GS volume.
Definite MT is tissue not included in PTVdel but lies within both the union of CTVs and
the GS volume.
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De f initeMT (%) =
GS−GS∩PTVdel
GS
×100 (8.3)
Ideally, there would be no MT within the GS volume.
Potential MT is tissue not included in PTVdel or the GS volume, but is within the union
of CTVs.
PotentialMT (%) =
CTVUnion− (CTVUnion∩PTVdel)−GS+(GS∩PTVdel)
GS
×100
(8.4)
The number of instances exceeding 5% potential MT averaged across all patients would
be a logical tolerance based on the remaining 5% of tissue left in a successful CTV
coverage of > 95%. However, the number of instances exceeding 10% potential MT was
considered for a more lenient approach incorporating the impact of interpolation
errors.
Definite EIT refers to tissue that is included within PTVdel but not in the GS or the union
of CTVs.
De f initeEIT (%) =
PTVdel− (CTVUnion∩PTVdel)
GS
×100 (8.5)
For each patient, the GS volume was expanded by 5 mm in all cardinal directions to
obtain a PTV volume in line with published clinical whole breast radiotherapy practices
[75, 178, 179]. The percentage volume difference between the resulting volume and the
GS volume was determined to be on average 37%. The tolerated amount definite EIT was
therefore accepted to be less than 37% of the union of CTVs.
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Figure 8.3: Whole breast CTV laterality, average volume and range (bars) for each
patient in the cohort. Each patient’s category based on average whole breast volume.
8.3 Results
8.3.1 Implementation
The laterality, range of volumes and average volume for each patient within the patient
cohort are outlined in Figure 8.3. Small, medium and large volume categories were
defined as 0-700 cm3, 701-1400 cm3 and 1401-2100 cm3 respectively based on the
distribution of CTV volumes across the cohort.
The margin magnitude in the cardinal directions and other selected directions for each
margin approach and volume category are presented in Table 8.1. Although no polar
margin expansion was explicitly applied in the z direction, the variation in start and finish
slices of contours used in margin determination resulted in a variable Z component to the
margin application.
Application of the different margin approaches is visually depicted in Figure 8.4, showing
the three-dimensional encompassment of the GS contour by PTVdel,GS.
Table 8.1: MDU magnitudes in cardinal directions (mm). Right and left categories are subdivided into small, medium and large categories.
Category System Right (mm) Left (mm) Ant (mm) Post (mm) Sup (mm) Inf (mm)
Right Small
Spherical 5.4 5.4 4.5 7.2 5.2 11.2
Polar 5.0 6.1 3.0 9.1 - -
Conventional 4.1 1.6 4.2 9 6.7 8.3
Right Medium
Spherical 7.2 7.2 6.3 11.5 5.2 8.3
Polar 6.5 9.7 7.2 11.2 - -
Conventional 5.7 2.4 6.3 11.4 6.2 7.2
Right Large
Spherical 12.8 12.8 10.1 13.5 3.5 3.9
Polar 14.2 16.1 10.7 17.6 - -
Conventional 9.8 3.8 10.1 13.4 3.7 3.7
Left Small
Spherical 4.6 4.6 3.2 5.9 5.8 7.3
Polar 4.5 4.5 3.6 6.1 - -
Conventional 5.0 5.9 3.2 5.8 6.3 6.8
Left Medium
Spherical 14.5 14.5 12.0 13.9 9.7 15.4
Polar 13.1 10.0 12.9 12.7 - -
Conventional 15.5 15.8 12 14.1 11.6 13.6
Left Large
Spherical 6.1 6.1 5.1 12.6 8.8 6.9
Polar 8.9 5.0 4.0 12.5 - -
Conventional 6.4 6.9 5.1 12.7 8.1 7.6
Figure 8.4: PTVdel,GS (green) defined using (a) polar, (b) spherical and (c) cartesian coordinates compared to the GS volume (blue) in
three dimensions for a medium sized left breast patient. X corresponds to lateral (negative)/medial (positive), y corresponds to anterior
(positive)/posterior (negative) and z corresponds to superior (positive)/inferior (negative).
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The main visual difference in margin approaches occurred in the anterior-medial and
posterior-lateral directions in which inter-observer variation for whole breast
radiotherapy is known to be largest [23].
Consistent coordinate system failure, corresponding to the maximum MDU values
averaged over all datasets in each volume category (Table A.7), occurred most often
between theta angles 0◦ and 90◦ for polar defined margins and between 270◦ and 360◦
for spherically defined margins. Excluding one outlier patient, this occurred on average
in (1.35 ± 2.29)% of data points for polar margins and (0.56 ± 1.34)% of data points for
spherical margins. The impact of this coordinate system failure on the overall volume
was minimal as evidenced by high DSC values for the original structures and the
interpolated structures (Table A.8). Average DSC across all structures when using a
polar interpolation method was 0.95 ± 0.05 and for spherical interpolation was 0.98 ±
0.02. A DSC of 1 indicates identical volumes.
8.3.2 Assessment
Comparing the MDU derived using the whole cohort to the MDU derived using the
volume specific method, a volume specific MDU resulted in significantly greater scores
for all margin approaches (p< 0.001 each for polar, spherical and cartesian). Although
there was significantly more definite EIT included for volume specific, spherically
defined (p< 0.001), there was significantly less definite MT for polar margins (p = 0.04)
and less potential MT for spherical MDUs (p = 0.01).
These results show that the use of volume categories in MDU derivation produced the
most favourable results overall compared to utilising the whole cohort. This is likely
because a margin defined on target volumes that varies largely in shape and size, is
expected to account for delineation uncertainty in an average target volume well, but
outlier volumes poorly. Volume categories were therefore utilised for the delineation
margin assessment. The results of the CTV coverage, EIT and MT are presented for a
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Table 8.2: Successful coverage of CTVs due to application of delineation margin to
different target volumes. ’Av’ is shortened from ’average’.
Small GS Large
Polar 110/168, Av = 95.4% 150/168, Av = 98.1% 152/168, Av = 98.5%
Spherical 85/168, Av = 94.0% 151/168, Av = 98.3% 161/168, Av = 99.2%
Conventional 138/168, Av = 96.9% 164/168, Av = 98.8% 164/168, Av = 98.9%
volume specific MDU.
Applying the MDU to the smallest, largest and GS volumes, the coverage of PTVdel with
each CTV was determined. Successful coverage was achieved for most CTVs regardless
of target volume size, with greater than 95% coverage occurring in 412/504 (81.7%) cases
(21 patients, 8 observers, 3 target volumes) for polar defined margins and 397/504 (78.8%)
cases for spherically defined margins. For the conventional method of margin expansion,
greater than 95% overlap occurred in 466/480 (92.4%) cases. The results were averaged
over all contours and all patients in each volume category and are presented in Figure
8.5.
Table 8.2 outlines the differences in the number of CTVs successfully covered by the
MDU specific to the target volume the margin was applied to, as well as the average
coverage in each category. Each category contains 168 data points corresponding to 21
datasets and 8 observers.
Average coverage of CTVs by a MDU is high, with > 95% for all margin approaches and
all target volumes, except for spherical MDUs applied to small target volumes. Coverage
is observed to increase and the SD decreases as target volumes increase. This can be
explained by considering the relative size of the CTVs being encompassed. PTVdel,largest
can be expected to encompass more CTVs than PTVdel,smallest because the target volume
it is applied to is larger than all other CTVs. This is not expected to occur in all cases
however, since target volume may be shifted, and the shape may vary. Perfect overlap of
all CTVs in all cases may not be achieved if CTVs are shifted relative to PTVdel.
The statistical differences in CTV overlap between pairs of margin approaches were
Figure 8.5: Overlap of PTVdel with observer CTVs, averaged (with SD) within each volume category. Delineation margin applied to (a) small,
(b) GS and (c) large target volumes.
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assessed (Table A.9). Summarising, conventional margin scores are significantly greater
than both anisotropic approaches for small target volumes. For GS target volumes,
conventional margin scores are significantly greater than cylindrical margin scores. For
large target volumes, spherical margin scores are significantly greater than conventional
margin scores, which in turn are greater than polar margin scores. These significance
results may be due to the fact that as whole breast CTVs increase in volume, they
become more spherical and hence the SD in delineation uncertainty for these shapes is
better described in spherical coordinates.
The amount of MT averaged across all structures and patients in each volume category is
presented in Figure 8.6.
The amount of potential MT within the 10% limit in 39/63 (61.9%) cases (21 datasets
and 3 target volumes) for polar margins, 36/63 (57.1%) cases for spherical margins and
42/60 (71.4%) cases for conventionally defined margins. This indicates that in the
majority of cases, all delineation margin approaches missed a tolerated amount of
potential tissue. Generally, margins applied to small target volumes and GS volumes
failed to meet tolerance more frequently than large target volumes because PTVdel,largest
often includes more tissue, reducing the chance of missing tissue. For small target
volumes, right breast patients had larger amounts of potential MT when using a
conventionally defined margin than left breasted patients perhaps due to differences in
contouring of especially crescent shaped target volumes close to the chest wall, where
particular attention may be paid to left breast volumes because of the proximity of the
heart.
For definite MT, 0/63 (0%) cases met the zero tolerance criteria for polar margins,
however 41/63 (65.1%) cases missed less than 1% of the GS volume. For spherically
defined margins, 31/63 (49.2%) cases met the zero tolerance criteria and 44/63 (69.8%)
missed less than 1% of the GS volume. For conventionally defined margins, 1/63 (1.6%)
cases met the zero tolerance criteria and 57/63 (90.5%) missed less than 1% of the GS
Figure 8.6: Definite and potential components of the tissue missed by the delineation margin averaged within each volume category for polar,
spherically and cartesian defined margins. Delineation margin applied to (a) small, (b) GS and (c) large target volumes.
Figure 8.7: Definite and potential components of the extra tissue encompassed by the delineation margin averaged within each volume category
for polar, spherically and cartesian defined margins. Delineation margin applied to (a) small, (b) GS and (c) large target volumes.
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volume. These results show that although some tissue was missed, it is a minimal
fraction of the GS volume in the majority of cases.
The amount of EIT included in PTVdel averaged across all structures and patients in each
volume category is presented in Figure 8.7. Definite and potential components are
shown.
The amount of definite EIT fell within the < 37% tolerance for the majority of patients
and target volumes, with 60/63 (95.2%) cases including less than 37% of the GS for
polar margins, 56/63 (88.9%) cases for spherical margins and 61/63 (96.8%) cases for
conventionally defined margins. This indicates that no delineation margin approach
includes excessive normal tissue. Generally, MDUs applied to the largest volume failed
to meet tolerance more frequently than other target volumes probably because remaining
CTVs smaller and more likely to be easily encompassed, resulting in the inclusion of
greater excess normal tissue.
The results of the pairwise statistical analysis comparing margin approaches for definite
EIT, potential MT and definite MT is presented in Tables A.10, A.11 and A.12. The
Wilcoxon Signed Rank Test was used with p< 0.05 significance and scores are presented
as the data is negatively skewed.
The results from Tables A.10, A.11 and A.12 indicate that a conventional margin misses
less definite MT for small volumes and includes less EIT for GS volumes. Although
missing less potential MT, a polar approach misses less definite EIT than a conventional
approach for large target volumes. As mentioned earlier, this trend towards the benefit of
an anisotropic with increasing target volume may be due to use of a coordinate system
that better describes the changing CTV shape for large target volumes.
The location of MT and EIT relative to organs at risk is important. Figure 8.8 visually
depicts the encompassment of PTVdel,GS with the union of CTVs for a dataset
representative of the patient cohort. There is little MT observed overall which reflects the
low potential MT and definite MT values determined. EIT occurs mostly in the
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Figure 8.8: Comparison of total missed tissue (dark grey), total extra tissue (light grey)
due to polar, spherically and cartesian defined PTVdel,GS (black) for a medium volume
left breast patient. Medial, superior and inferior slices are shown.
anterior-medial and posterior-lateral directions for polar and spherical approaches and
occurs in all directions for the conventional approach. The added tissue at the chest wall
for a conventional margin may impact lung doses. EIT at the breast surface is minimal
due to clipping of the margin here.
8.4 Discussion
It is acknowledged that there is justification for a delineation margin in radiotherapy [14,
159, 169]. Although derived for CTV shifts and displacements as opposed to shape
deformations, a 2.5Σ margin for systematic uncertainties has been shown to be valid in
accounting for delineation uncertainty [14, 180]. Furthermore, Peulen et al validated that
the required MDU in non-small cell lung tumours is 2.8Σ and Pogson et al proposed a
whole breast radiotherapy margin of 2Σ [159, 169]. However these studies defined
margins that did not explicitly investigate the spatial dependence of delineation
uncertainty across the whole target surface and therefore may not have adequately
accounted for delineation uncertainty in regions of largest variation. Other studies have
CHAPTER 8. DEFINING A DELINEATION MARGIN 111
utilised polar coordinates to determine inter-observer variability [38, 127] and have
proposed isotropic MDU approaches [174], however this is the first study to combine
these and assess the outcome. This study uses whole breast as an example case and
provides the first investigation on an anisotropic delineation margin accounting for
contouring uncertainty where it is largest. The anisotropic approach has been compared
to conventional margin application approaches where cardinal cartesian margins are used
enabling an assessment on the need to determine delineation uncertainty margins
differently to other uncertainties in clinical margin definitions. This study also presents a
novel approach to assessing the impact of treatment margins considering both cancerous
tissue that may not be included within a margin and normal tissue that is included within
a margin.
8.4.1 Implementation
The margin magnitudes determined in this study, range from 3.2-14.5 mm for spherical
margins (average 8.3 mm), 3.0-17.6 mm for polar margins (average 8.9 mm) and 1.6-
15.8 mm for cartesian defined margins (average 7.8 mm) across all volume categories and
cardinal directions. Peulen et al, obtained an isotropic GTV to PTV margin for non-small
cell lung cancer ranging from 3.4-5.9 mm [159]. This is smaller than the values obtained
in this study however the SD determined in their study was relatively small (1.2-1.8 mm)
and the anatomical site tested was different. A typical whole breast radiotherapy CTV
to PTV margin expansion used in clinical practice is 5 mm expansion in the cardinal
directions. The average magnitudes of this delineation margin are larger than that of
clinical margins however this may be attributed to the fact that clinical margins often do
not incorporate delineation uncertainty and do not spatially vary across the target volume
surface.
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8.4.2 Assessment
A delineation margin for whole breast radiotherapy has been effectively implemented,
showing acceptable observer CTV coverage (> 95% in the majority of cases) and
minimal EIT and MT for a weighting factor of α=2. Both anisotropic and conventional
approaches produced favourable results, however defining a margin in the cardinal
directions as is done clinically, is most appropriate for small and GS volumes. For small
target volumes, a conventional approach produces significantly greater overlap of CTVs,
less definite EIT and less potential MT. For GS target volumes, significantly greater
overlap and less definite MT is achieved for a conventional approach. This is despite the
largest delineation uncertainty occurring in regions outside these six main directions.
This suggests that delineation uncertainty margins for target volumes < 1400 cm3 are
not sensitive to inter-observer variation outside the cardinal directions.
For large target volumes however, there is a need for a delineation margin to be anisotropic
to account for spatially varying inter-observer variation. Significantly greater overlap
occurs with this approach as opposed to a conventional approach, and significantly less
definite EIT and definite MT occur. Specifically, a spherically defined margin is most
appropriate, with more favourable significant results as compared to a polar approach.
This difference for large target volumes in the most appropriate margin approach may be
due to the fact that large target volumes are more spherical in nature and are therefore
better described using spherical coordinates.
The implementation of the proposed delineation margin may impact patient outcomes. A
study classifying local disease recurrences after breast conserving surgery and
radiotherapy found that most recurrences occur in the upper two quadrants of the breast
[181]. Radiotherapy in the anterior region of breast CTV must therefore be highly
precise to enhance effectiveness of the treatment. The assessed anisotropic delineation
margin will help achieve this goal for large target volumes, as it explicitly accounts for
the higher inter-observer variation in the anterior-medial direction of whole breast target
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volume. For all other target volumes, a conventional delineation margin approach is
adequate to account for this variation.
This study has proposed and implemented a MDU that adequately accounts for inter-
observer variation in whole breast radiotherapy. Future work may involve optimising the
weighting factor improve coverage, ET and MT across the entire cohort.
8.4.3 Limitations
There are limitations in using a radial-based method for defining the spatial variation in
target volume delineation, with radial projections potentially inadequate in describing
the target shape. However, a radial-based method is necessary in order to easily and
consistently re-produce points at which to define and apply the margin across different
structures and different patients. Acknowledging these limitations, this study utilises
basic coordinate systems in this first instance of defining a delineation margin, so as not
to overcomplicate the method. More advanced mathematics could have been used, such
as multiple coordinate systems, however this would likely result in the same problems
due to inherent inconsistencies in whole breast radiotherapy contours across observers
and patients.
This inherent limitation was found to have minimal impact on the approach, with on
average, < 1.5% of data points for a polar margin and < 0.6% for a spherical margin
affected. High DSC values (> 0.94 for polar and > 0.98 for spherical) between
interpolated structures and original structures support this. Using this method for
defining a delineation margin for more spherically shaped volumes like prostate, would
likely yield an even smaller error [176].
A cohort consisting of N = 8 observers was assumed to be adequate in producing a normal
distribution for SD calculation since there was noticeable variability in delineation. In
the event that a smaller number of observers were to be used or there was insufficient
variation amongst observers, for example, 8 observers that consistently delineate smaller
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target volumes compared to their peers, the delineation margin would be highly dependent
on the input delineations and hence limited in its widespread accuracy. As the number of
observers increases, the more applicable the margin is in effectively accounting for a range
in delineation uncertainty.
This study was designed as a preliminary investigation into methods for accounting for
delineation uncertainty in a spatially varying sense. The whole breast CT dataset was
used primarily as it was an available dataset in which to develop this methodology. This
methodology assumes an idealistic scenario where setup and motion uncertainties are
minimal, reflecting the direction modern radiotherapy is approaching. A more realistic
scenario for current radiotherapy practice would be to include delineation uncertainty
with methods for accounting for existing treatment uncertainties. The optimum way to
combine an anisotropic delineation margin with existing uncertainty margins and in
treatment planning systems, warrants further investigation.
Chapter 9
Discussion
This thesis has presented a body of work investigating the magnitude of inter-observer
variation, its impact on the radiotherapy process and how best to manage its presence.
Although two specific treatment sites were investigated, the concepts and methods
presented can be applied to any radiotherapy treatment site.
Inter-observer variation can be quantified, understood, minimised and managed by
following the methods outlined in this thesis. Chapters 3 and 5 provide examples of the
ways inter-observer variation can be quantified using a number of volumetric and
dimensional metrics. It is important to quantify the magnitude of inter-observer variation
such that its relative importance with respect to other uncertainties in the radiotherapy
treatment process can be determined. Also, the SD of this uncertainty is required if it is
to be incorporated into uncertainty margins. However, once the magnitude of
inter-observer variation is known, it is clinically important to determine the impact it has
on treatment outcomes. Chapters 3, 4 and 5 outline how to determine to what extent
inter-observer variation impacts DVH parameters in a patients treatment plan. Chapters
4 and 5 further demonstrate how DVH parameters can be correlated with contouring
metrics such that a delineation can be evaluated with respect to the resulting treatment
plan. With the magnitude and impact of inter-observer variation known, attempts to
minimise its impact can be implemented. Chapter 6 provides an example of one such
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method to minimise inter-observer variation by automating the delineation process
whilst maintaining the value provided by subjective interpretation of imaging datasets by
clinicians. However, inter-observer variation remains despite these efforts as long as the
’ground truth’ target volume remains unknown. Hence, Chapter 7 and 8 investigate
methods to account for the remaining inter-observer variation by defining and applying a
margin to account for it. This method aligns with the current procedure of CTV to PTV
expansions for other uncertainties.
The cumulative outcome of this body of work is a workflow for managing inter-observer
variation that can be useful for clinical trials and in individual treatment centres; first
assessing current variation, considering the dosimetric impact of this and then
investigating margins to account for this where necessary. Adhering to this workflow
before commencing clinical trials would enable consistency in treatment planning and
dose reporting such that trial interventions can be clearly assessed. Individual treatment
centres can follow this workflow to characterise and customise their procedures for their
specific patient cohort.
9.1 Research Aims
The specific aims of this body of work are addressed below.
Aim 1. Understand the impact of delineation uncertainty on radiotherapy efficacy
Research questions:
What is the magnitude of inter-observer variation for high dose rate
cervical cancer brachytherapy in the Australian context?
Chapter 3 quantified the variability in CTVHR delineation for HDR cervical
cancer brachytherapy in the Australian context and assessed the dosimetric
consequences of this variation on a gold standard target volume.
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Inter-observer variation has been shown to be present in the case of HDR
cervical cancer brachytherapy. Chapter 3 found that overall, CTVHR
contouring was relatively consistent with an average DSC of ≥ 0.7
occurring in 8/10 cases assessed on the STAPLE gold standard, and in
6/10 cases assessed on the consensus contour. However, there was a wide
range in variability when considering each individual contour, with an
average MASD of 7.13 ± 6.37 mm and an average DSC of 0.63 ± 0.15.
Chapter 5 quantified spatially descriptive contouring metrics for the
CTVHR inter-observer variation in the same dataset used in Chapter 3. The
location of the lateral, anterior/posterior and superior/inferior positions of
the COM relative the gold standards COM varied on average 0.16 cm, 0.27
cm and 0.87cm respectively. The maximum dimensions demonstrated 0.75
- 1.82cm variation and a mean volume variation of 28.5 cm3 was observed.
How does inter-observer variation affect the dosimetric parameters
obtained during the radiotherapy treatment planning process?
The inter-observer variability in HDR cervix brachytherapy observed in
the Chapter 3 translated to a dosimetric variability. A gold standard plan
optimised to the gold standard contours was assessed on each observer
contour. The average relative standard deviation in D90 across all patients
was 27% and 28% respectively for the STAPLE and consensus plans. The
average standard deviation in D100 was 34% and 35% respectively for the
STAPLE and consensus plans. The average dosimetric uncertainty in
CTVHR for an individual fraction (with a prescription of 8 Gy) due to
inter-observer variation was approximately 1.5 Gy.
The dose planning variation that arises from inter-observer variation when
individual plans are optimised to individual contours was assessed in
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Chapter 4. Over the course of a four-fraction treatment, 2.9 - 3.4 Gy
EQD210 uncertainty was observed for the CTVHR depending on which
gold standard contour was used for reporting. The single fraction
variability was 4.5 - 6.0%. This is substantially smaller than the results
found in Chapter 3, however it is pertinent to highlight to the reader that
the methodologies of these two studies were fundamentally different as
outlined in Figure 4.1.
Chapter 5 utilised the dataset of Chapter 3, but applied the same
methodology as in Chapter 4. For an entire four fraction brachytherapy
course, CTVHR D90 varied by 1.9 Gy for the STAPLE contour and 2.8
Gy for the STAPLE contour. This is slightly smaller variability than
observed in Chapter 4, likely due to the differences in the datasets as
outlined in Table 5.6.
Do common metrics used to assess contouring consistency correlate
with dosimetric outcomes?
Volume and maximum dimension metrics used to quantify the
magnitude of inter-observer variation were shown in Chapter 4 to
correlate with CTVHR D98. Specifically, a decrease in the lateral,
anterior/posterior and superior/inferior dimensions correlate most with an
increase in D98. These correlations were weak to moderate in strength.
This was validated in Chapter 5 using an independent dataset. The
correlations between lateral dimensions and D98, as well as volume and
D98 were found to be statistically the same between both datasets.
Aim 2. Minimise delineation uncertainty by automating the contouring process
Research questions:
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Can an accurate automatic segmentation method be defined to reduce
the magnitude of delineation uncertainty?
Chapter 6 proposed and investigated an atlas-based auto-segmentation
method that was shown to accurately contour whole breast external
beam radiotherapy target contours in less than 4 minutes on average.
The auto-segmented contours had good similarity when compared to the
gold standard STAPLE contour with a DSC > 0.7 and a MASD < 1 cm.
The utilisation of this approach in the radiotherapy treatment planning
process would eliminate inter-observer variation arising from manual
contouring.
Aim 3. Manage delineation uncertainty using an uncertainty margin
Research questions:
What is the best coordinate system to define a delineation uncertainty
margin for whole breast external beam radiotherapy?
For a whole breast external beam radiotherapy dataset, a cylindrical
coordinate system is most appropriate for defining a delineation
margin than cartesian coordinates due to the hemi-spherical shape of
the target volumes. Chapter 7 demonstrated that for the central slice, the
standard deviation in contour dimension peaked medially at 15◦ (3.55 cm)
for right breast datasets and 171◦ (1.44 cm) for left breast datasets,
indicating the largest inter-observer variation occurs anterior-medially.
Cartesian coordinates cannot accurately describe the hemispherical breast
shape in these regions, therefore are inadequate at defining an anisotropic
delineation uncertainty margin.
Chapter 8 extended the work in Chapter 7 to investigate spherical
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coordinate systems. This study highlighted the difficulty in using any
coordinate system based on radial projections from a central point for
contours that are hemispherical. Nevertheless, a spherically defined
delineation uncertainty margin was deemed to be most appropriate
for large breast target volumes (> 1400 cm3) due to the increase
coverage of the margins. This is likely due to the added superior-inferior
information available that is otherwise lost with polar coordinate systems.
Defining a margin in the cardinal dimensions (cartesian coordinate
system) as is done clinically for other uncertainties, is most appropriate for
small volumes (<1400 cm3) as these volumes are less sensitive to
inter-observer variation outside the cardinal directions.
Can inter-observer variation be accounted for appropriately with an
uncertainty margin?
A whole breast external beam radiotherapy delineation margin to
account for inter-observer variation has been defined and applied in
Chapter 8. Delineation uncertainty margin magnitudes ranged from
3.2-14.5 mm for spherically defined margins 3.0-17.6 mm for polar
margins and 1.6 -15.8 mm for Cartesian defined margins. Acceptable CTV
observer coverage was determined with > 95% of observer contours
including in the delineation margin for all coordinate systems.
’Extra-included tissue’, that is, tissue not contoured by any observer and
’missed tissue’ which refers to tissue contoured by at least one observer,
but not covered by the delineation uncertainty margin were within the
accepted tolerances for the majority of cases.
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9.2 Future Work
At the conclusion of this work, there is scope for further investigation in a number of
areas.
The atlas-based method for auto-segmentation proposed in Chapter 6 utilised an
approach that was the most advanced and common approach at the time of publication.
In the following years, automatic segmentation techniques have expanded into the realm
of machine-learning techniques. An investigation utilising a similar methodology but
applying machine-learning algorithms to delineate target volumes is warranted. This
approach would offer increased accuracy and increased speed in delineation.
The delineation margin proposed in Chapter 8 relies on an origin based coordinate system.
This dependence introduces limitations for non-spherical target volumes. This work could
be expanded to investigate deformedly registered datasets in which the margin is defined
based on surface variations between observers. Additionally, with an idealistic move away
from binary contours to probabilistic target regions, a conceptual delineation uncertainty
probability map could be defined as opposed to delineation uncertainty margin. This
would enable treatment planning isodoses to be conformed to isolines representing the
likelihood of observer agreement. As such, the impact of inter-observer variation would
be further reduced.
Finally, this thesis investigated specific aims on available retrospective datasets. It would
be interesting to repeat the work for other treatment sites, especially the delineation
margin study which could be assessed for robustness on different treatment sites.
Chapter 10
Conclusion
The resulting outcome of this thesis is a workflow that can be utilised to improve the
accuracy of patient cancer treatments.
This thesis has demonstrated that inter-observer variation is present and for some
specific patients, substantial, for high-dose rate cervical cancer brachytherapy. Although
the presence of any uncertainty is reason for pause in radiotherapy, the more pertinent
question is whether the presence of inter-observer variation has an impact on the
treatment plan delivered to the patient. For both European GEC-ESTRO and Australian
datasets, the dosimetric impact was demonstrated to be substantial, indicating that
methods to manage this uncertainty should be investigated.
Acknowledging that inter-observer variation should be reduced where possible, this
thesis investigated a method to automatically contour target volumes (with specific
application to whole breast radiotherapy) such that inter-observer variation arising from
human judgment might be eliminated. It was shown that an atlas-based
auto-segmentation algorithm can quickly and accurately delineate target volumes.
However, manual review of the auto-contour is recommended and manual adjustments
would re-introduce inter-observer variation.
After demonstrating that inter-observer variation has a large dosimetric impact and that
its presence remains, even after minimising the human element in contouring, this thesis
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has investigated a margin to manage this uncertainty. Margins used in radiotherapy are
the current convention for accounting for uncertainties in the treatment process. A proof
of concept delineation margin was proposed and investigated for whole breast
radiotherapy. Despite limitations in this method, it is a successful proof of concept in
effectively managing delineation uncertainty in radiotherapy.
Overall, this thesis acts as a guide in how to quantify, understand and manage
inter-observer variation when implementing a new technique in a clinical department or
clinical trial such that radiotherapy can be delivered accurately and safely for every
patient.
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Table A.1: Cervix brachytherapy applicator specifications.
Case Applicator Length (mm) Ring Diameter (mm) Number of Needles
1 30 40 9
2 34 60 5
3 30 60 5
4 30 60 9
5 30 40 5
6 30 40 5
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Table A.2: EQD210 (Gy) prescribed doses for plans optimised to each observer contour.
CTVHR D90 CTVHR D98 CTVIR D98 GTV D98 Bladder D2 cm3 Sigmoid D2 cm3 Rectum D2 cm3
P
a
t
i
e
n
t
1
Master 91.0 83.1 62.6 100.4 77.7 53.6 69.1
STAPLE 90.6 83.2 64.1 91.1 77.0 56.9 69.8
Observer 1 90.6 80.8 65.4 98.1 72.0 53.9 69.1
Observer 2 90.1 81.5 59.4 98.5 77.2 53.6 68.9
Observer 3 91.5 81.7 61.3 92.7 77.2 65.7 58.5
Observer 4 94.2 84.2 62.1 96.4 73.0 53.9 67.0
Observer 5 89.9 79.6 60.4 95.1 76.7 55.3 69.1
Observer 6 89.7 79.6 60.5 97.9 83.1 54.7 69.2
Observer 7 90.0 81.9 63.0 90.4 77.3 54.7 66.0
Observer 8 94.7 85.4 61.7 89.6 78.4 64.8 62.6
Observer 9 94.5 86.3 62.9 95.7 77.1 53.6 69.1
Observer 10 93.6 85.4 63.6 104.7 75.3 54.0 68.5
P
a
t
i
e
n
t
2
Master 90.6 82.4 60.2 93.8 74.9 60.5 49.7
STAPLE 89.8 80.5 60.3 94.6 83.7 60.1 50.4
Observer 1 89.3 78.8 62.3 102.3 82.5 64.0 50.9
Observer 2 96.6 89.8 57.3 96.7 79.9 60.5 50.5
Observer 3 92.3 83.2 59.3 94.3 76.0 57.2 46.6
Observer 4 93.6 83.4 60.1 94.5 82.2 60.0 50.0
Observer 5 89.4 80.2 64.8 97.5 81.4 63.7 50.2
Observer 6 85.0 71.8 57.0 96.4 85.8 70.0 52.0
Observer 7 90.2 80.7 61.8 93.8 82.9 62.9 47.7
Observer 8 92.4 82.7 60.0 83.0 84.4 61.3 49.1
Observer 9 92.5 82.6 58.9 94.6 78.6 61.6 49.9
Observer 10 90.6 81.2 62.7 94.7 81.2 62.9 49.6
Table A.2 – Continued on next page
Table A.2 – Continued from previous page
CTVHR D90 CTVHR D98 CTVIR D98 GTV D98 Bladder D2 cm3 Sigmoid D2 cm3 Rectum D2 cm3
P
a
t
i
e
n
t
3
Master 88.3 80.2 59.9 102.2 75.5 53.5 68.6
STAPLE 85.8 76.4 57.3 100.0 74.5 54.1 70.8
Observer 1 86.3 75.4 63.2 108.3 82.5 53.7 70.0
Observer 2 80.0 69.7 55.1 93.3 74.1 56.5 70.9
Observer 3 - - - - - - -
Observer 4 89.8 81.9 60.3 102.7 70.5 53.2 68.8
Observer 5 78.9 69.1 58.9 88.3 78.4 56.2 70.7
Observer 6 85.7 73.8 56.1 98.5 80.8 55.5 70.8
Observer 7 86.0 73.5 58.1 92.3 74.6 59.3 70.3
Observer 8 92.3 80.7 59.5 94.2 71.1 63.1 69.7
Observer 9 91.6 79.2 58.6 103.0 74.5 53.7 69.4
Observer 10 90.0 81.8 61.1 99.1 76.4 56.4 69.9
P
a
t
i
e
n
t
4
Master 87.1 75.0 57.3 117.9 85.7 67.1 55.0
STAPLE 81.9 69.1 56.1 88.8 85.9 67.9 56.0
Observer 1 81.9 68.3 58.2 110.3 85.6 70.4 57.5
Observer 2 85.6 70.9 55.2 126.7 86.0 67.2 56.5
Observer 3 88.9 76.0 56.2 88.0 83.0 68.7 52.5
Observer 4 86.8 76.2 55.6 110.9 85.9 68.5 53.9
Observer 5 85.9 74.0 58.7 103.1 83.1 66.2 51.9
Observer 6 76.2 63.7 54.9 98.2 85.9 67.5 54.7
Observer 7 80.3 68.3 57.5 102.1 85.9 70.0 52.6
Observer 8 73.0 63.2 54.5 67.3 87.1 67.8 51.4
Observer 9 80.5 65.5 54.2 123.1 85.8 69.5 55.0
Observer 10 83.3 70.7 56.8 84.8 85.3 70.9 56.5
Table A.2 – Continued on next page
Table A.2 – Continued from previous page
CTVHR D90 CTVHR D98 CTVIR D98 GTV D98 Bladder D2 cm3 Sigmoid D2 cm3 Rectum D2 cm3
P
a
t
i
e
n
t
5
Master 87.6 80.0 60.6 100.4 78.0 62.3 66.0
STAPLE 90.5 83.0 62.0 94.3 82.0 60.4 69.9
Observer 1 91.0 77.1 60.7 126.2 84.0 57.6 68.3
Observer 2 84.8 74.7 54.8 113.5 82.2 57.8 70.5
Observer 3 92.0 84.2 61.3 94.6 76.8 56.5 62.7
Observer 4 93.6 85.7 58.6 94.5 82.9 60.5 65.0
Observer 5 90.5 75.6 58.3 109.6 77.2 60.4 69.0
Observer 6 91.0 80.5 59.3 105.8 77.3 58.3 70.1
Observer 7 90.5 80.0 61.2 94.5 80.2 61.1 66.8
Observer 8 95.0 83.8 56.8 91.3 84.0 60.8 66.7
Observer 9 91.0 80.2 59.5 120.3 78.2 57.9 61.8
Observer 10 90.3 80.8 61.2 103.3 78.0 61.2 68.1
P
a
t
i
e
n
t
6
Master 92.1 78.7 63.2 84.5 83.7 68.7 66.1
STAPLE 83.8 72.0 58.1 83.4 85.6 70.4 67.6
Observer 1 85.9 74.7 60.7 98.5 81.0 66.3 64.5
Observer 2 79.9 67.0 55.2 75.9 85.7 70.1 65.3
Observer 3 85.6 66.7 55.0 107.1 85.9 69.9 55.3
Observer 4 85.9 69.0 58.1 91.9 85.1 67.4 65.4
Observer 5 67.3 59.3 54.0 72.8 85.8 69.7 64.6
Observer 6 87.4 76.5 58.2 89.7 85.0 70.1 68.6
Observer 7 87.4 76.8 59.4 88.9 85.2 68.3 64.8
Observer 8 85.5 75.6 51.7 80.5 85.8 67.0 63.8
Observer 9 86.8 72.5 57.6 92.9 83.9 70.1 66.0
Observer 10 86.0 72.0 58.8 91.2 85.7 66.0 62.9
Table A.3: Single fraction mean, SD and rSD for all dosimetric parameters and all target contours, averaged across all observers for each patient.
STAPLE EC
Case 1 2 3 4 5 6 Mean 1 2 3 4 5 6 Mean
CTVHR D90
Mean (Gy) 7.9 7.4 7.3 6.1 7.5 6.9 7.2 7.7 8.2 7.4 7.2 7.7 7.9 7.7
SD (Gy) 0.4 0.5 0.2 0.7 0.6 0.2 0.4 0.3 0.4 0.2 0.4 0.5 0.2 0.3
rSD (%) 4.8 6.9 3.4 10.6 7.8 2.6 6.0 4.3 4.8 2.9 6.2 6.3 2.3 4.5
CTVHR D98
Mean (Gy) 6.8 6.3 6.1 4.4 6.2 5.4 5.9 6.7 6.9 6.3 5.6 6.5 6.2 6.4
SD (Gy) 0.4 0.6 0.2 0.6 0.8 0.3 0.5 0.3 0.3 0.2 0.4 0.6 0.3 0.4
rSD (%) 5.4 8.8 4.0 12.6 13.3 4.6 8.1 4.7 5.1 3.4 6.7 10.0 4.3 5.7
CTVIR D98
Mean (Gy) 4.0 3.5 3.2 2.6 3.4 3.1 3.3 4.0 3.8 3.5 2.9 3.7 3.8 3.6
SD (Gy) 0.3 0.3 0.2 0.3 0.4 0.1 0.3 0.3 0.3 0.2 0.2 0.4 0.1 0.2
rSD (%) 6.9 9.0 5.0 11.2 12.5 4.0 8.1 6.4 6.9 5.7 7.3 9.9 3.5 6.6
GTV D98
Mean (Gy) 8.0 7.9 8.7 7.3 7.8 6.9 8.1 8.6 8.3 8.7 10.5 9.5 7.1 8.8
SD (Gy) 0.3 0.8 0.3 0.4 0.4 0.3 0.4 0.2 0.4 0.3 0.5 0.4 0.4 0.4
rSD (%) 4.0 10.1 3.3 5.4 5.2 4.8 5.3 2.6 4.3 3.4 4.8 4.4 5.0 4.1
Bladder D2 cm3
Mean (Gy) 5.3 5.7 5.3 6.2 5.6 6.1 5.7 5.2 5.5 5.0 5.9 5.7 6.0 5.5
SD (Gy) 0.2 0.2 0.4 0.4 0.4 0.2 0.3 0.2 0.2 0.4 0.4 0.4 0.2 0.3
rSD (%) 3.0 4.2 8.3 6.0 7.4 3.7 5.4 3.2 4.5 7.9 6.2 7.3 3.6 5.4
Rectum D2 cm3
Mean (Gy) 2.6 3.7 2.7 4.4 3.4 4.4 3.5 2.5 3.6 2.5 4.1 3.4 4.1 3.4
SD (Gy) 0.2 0.3 0.3 0.2 0.3 0.3 0.3 0.2 0.3 0.3 0.2 0.3 0.2 0.3
rSD (%) 8.6 9.3 9.9 4.2 8.5 5.8 7.7 8.5 9.1 10.3 4.1 8.6 5.5 7.7
Sigmoid D2 cm3
Mean (Gy) 4.6 1.9 4.7 2.8 4.5 4.2 3.8 4.3 1.8 4.3 2.6 4.1 4.0 3.5
SD (Gy) 0.2 0.1 0.1 0.2 0.3 0.2 0.2 0.2 0.1 0.1 0.2 0.3 0.1 0.2
rSD (%) 4.0 5.4 2.7 5.8 7.1 3.5 4.8 4.0 5.0 2.7 5.8 6.1 3.1 4.4
Table A.4: Spearmans non-parametric correlation coefficient results for the EC contour. Statistically significant results shown in bold italics.
x COM y COM z COM C COM MD-X MD-Y MD-Z Vol CI
ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig
CTVIR D98 0.15 0.22 -0.07 0.59 0.19 0.11 -0.02 0.86 -0.19 0.11 0.03 0.79 0.08 0.5 0.04 0.73 0.11 0.38
GTV D98 0.21 0.08 0.06 0.63 0.1 0.42 0.01 0.96 0.23 0.06 -0.16 0.18 -0.4 <0.01 -0.18 0.14 -0.33 0.01
Bladder D2 cm3 -0.13 0.27 -0.31 0.01 0.36 <0.01 0.26 0.03 -0.37 <0.01 -0.23 0.06 -0.34 <0.01 -0.69 <0.01 -0.47 <0.01
Rectum D2 cm3 -0.22 0.07 0.09 0.46 -0.3 0.01 -0.21 0.07 -0.52 <0.01 -0.48 <0.01 0.58 <0.01 0.37 <0.01 0.03 0.8
Sigmoid D2 cm3 0.24 0.04 -0.12 0.31 0.07 0.58 -0.12 0.32 -0.28 0.02 -0.2 0.1 0.47 <0.01 0.03 0.82 0.16 0.18
Table A.5: Spearmans non-parametric correlation coefficient results for the STAPLE contour. Statistically significant results shown in bold
italics.
x COM y COM z COM C COM MD-X MD-Y MD-Z Vol CI
ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig ρ sig
CTVIR D98 0.18 0.13 0.14 0.25 -0.07 0.55 0.12 0.34 -0.29 0.02 -0.31 0.01 -0.22 0.06 -0.21 0.08 0.1 0.41
GTV D98 -0.01 0.95 -0.06 0.60 0.17 0.15 0.10 0.43 -0.19 0.11 -0.19 0.11 -0.34 <0.01 -0.20 0.09 0.34 <0.01
Bladder D2 cm3 -0.03 0.79 0.02 0.85 -0.06 0.60 -0.16 0.19 -0.32 <0.01 -0.22 0.07 -0.40 <0.01 -0.70 <0.01 -0.36 <0.01
Rectum D2 cm3 0.18 0.46 0.19 0.12 -0.11 0.36 -0.03 0.81 -0.50 <0.01 -0.52 <0.01 0.60 <0.01 0.40 <0.01 -0.02 0.86
Sigmoid D2 cm3 -0.21 0.08 0.05 0.68 0.05 0.71 0.09 0.44 -0.24 0.05 -0.20 0.10 0.43 <0.01 0.05 0.67 0.04 0.73
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Table A.6: Single fraction prescribed doses (Gy) for plans optimised to each observer
contour.
CTVHR D90 Bladder D2 cm3 Rectum D2 cm3 Sigmoid D2 cm3
Pa
tie
nt
1
STAPLE 9.5 5.7 4.4 5.0
EC 10.9 5.5 4.2 4.7
Observer 1 8.3 4.9 3.7 4.3
Observer 2 8.4 5.3 4.2 4.7
Observer 3 9.4 4.8 3.8 4.3
Observer 4 9.4 4.9 3.7 4.1
Observer 5 8.0 5.7 4.3 5.3
Observer 6 9.2 5.3 4.2 4.6
Observer 7 9.9 4.9 3.9 4.5
Observer 8 9.1 5.0 3.7 4.4
Observer 9 9.1 4.9 3.9 4.4
Observer 10 9.6 4.7 3.6 4.1
Observer 11 9.8 4.7 3.7 4.0
Observer 12 9.6 5.1 4.0 4.4
Pa
tie
nt
2
STAPLE 4.3 6.5 5.9 0.9
EC 5.8 6.5 5.2 0.9
Observer 1 4.3 6.5 5.2 0.8
Observer 2 5.6 6.5 4.9 0.8
Observer 3 4.8 6.5 4.7 0.8
Observer 4 6.4 6.5 4.8 0.8
Observer 5 5.9 6.5 4.7 0.8
Observer 6 8.0 6.5 5.2 0.8
Observer 7 6.5 6.5 4.7 0.8
Observer 8 6.0 6.5 4.1 0.8
Observer 9 6.4 6.5 4.6 0.8
Observer 10 6.5 6.4 4.8 0.8
Observer 11 3.8 6.5 4.7 0.8
Observer 12 5.4 6.5 4.4 0.8
Table A.6 – Continued on next page
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Table A.6 – Continued from previous page
CTVHR D90 Bladder D2 cm3 Rectum D2 cm3 Sigmoid D2 cm3
Pa
tie
nt
3
STAPLE 2.5 6.5 5.3 2.6
EC 8.4 5.8 4.8 2.2
Observer 1 2.1 6.4 5.0 2.6
Observer 2 8.1 5.7 3.9 2.4
Observer 3 2.3 6.2 4.8 2.6
Observer 4 8.0 6.0 4.8 2.5
Observer 5 8.2 5.8 4.2 2.3
Observer 6 8.0 6.0 5.3 2.5
Observer 7 2.9 5.6 4.7 2.4
Observer 8 8.5 5.8 4.7 2.4
Observer 9 8.2 6.4 5.0 2.7
Observer 10 8.6 5.9 4.2 2.3
Observer 11 5.6 5.9 4.6 2.5
Observer 12 7.0 5.9 4.4 2.5
Pa
tie
nt
4
STAPLE 6.2 6.5 4.4 5.4
EC 8.9 6.2 4.2 5.2
Observer 1 5.7 6.4 4.1 5.2
Observer 2 7.6 6.5 4.0 5.1
Observer 3 6.7 6.5 4.2 5.3
Observer 4 9.0 6.4 4.0 5.2
Observer 5 6.3 6.5 4.2 5.3
Observer 6 8.6 6.4 4.4 5.3
Observer 7 4.0 6.5 4.2 5.3
Observer 8 8.2 6.4 4.1 5.2
Observer 9 7.7 6.5 4.2 5.3
Observer 10 7.1 6.4 4.2 5.3
Observer 11 6.9 6.5 4.2 5.3
Observer 12 8.6 5.9 3.8 4.8
Pa
tie
nt
5
STAPLE 4.9 6.5 3.7 3.9
EC 8.7 6.5 3.7 3.9
Observer 1 5.2 6.5 3.8 4.0
Observer 2 6.9 6.5 3.2 3.8
Observer 3 8.1 6.5 3.1 3.7
Observer 4 7.6 6.5 2.7 3.4
Observer 5 5.8 6.5 3.6 4.0
Observer 6 5.0 6.5 3.7 3.9
Observer 7 4.2 6.5 3.5 3.9
Observer 8 5.5 6.5 2.8 3.5
Observer 9 4.8 6.5 2.7 3.5
Observer 10 8.2 5.9 3.4 3.5
Observer 11 6.3 6.5 3.2 3.7
Observer 12 6.7 6.5 2.8 3.4
Table A.6 – Continued on next page
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Table A.6 – Continued from previous page
CTVHR D90 Bladder D2 cm3 Rectum D2 cm3 Sigmoid D2 cm3
Pa
tie
nt
6
STAPLE 0.9 6.4 5.9 -
EC 1.1 6.5 5.5 -
Observer 1 0.9 6.5 4.9 -
Observer 2 1.6 6.5 5.8 -
Observer 3 0.9 6.5 5.6 -
Observer 4 1.3 6.5 5.8 -
Observer 5 1.0 6.5 5.8 -
Observer 6 5.6 6.5 5.6 -
Observer 7 1.1 6.5 5.9 -
Observer 8 9.0 5.9 5.2 -
Observer 9 7.1 6.5 5.7 -
Observer 10 1.2 6.5 5.7 -
Observer 11 1.0 6.5 5.6 -
Observer 12 1.2 6.5 5.2 -
Pa
tie
nt
7
STAPLE 8.0 6.5 5.9 3.9
EC 8.3 5.9 5.2 3.5
Observer 1 8.0 5.6 5.3 3.4
Observer 2 8.0 5.9 5.0 3.6
Observer 3 8.4 5.9 5.2 3.6
Observer 4 8.5 5.9 5.1 3.6
Observer 5 7.9 6.5 4.4 3.8
Observer 6 8.6 6.5 5.8 3.9
Observer 7 8.7 6.5 5.9 3.9
Observer 8 8.7 6.5 5.4 3.9
Observer 9 8.1 6.5 5.5 3.9
Observer 10 8.7 5.9 5.3 3.5
Observer 11 8.3 6.5 5.1 3.8
Observer 12 8.7 6.5 5.2 3.9
Pa
tie
nt
8
STAPLE 6.7 6.4 4.4 5.9
EC 7.0 6.5 3.6 5.6
Observer 1 7.0 6.5 3.7 5.9
Observer 2 7.0 6.5 4.3 5.7
Observer 3 7.2 6.5 4.4 5.9
Observer 4 7.3 6.5 3.9 5.7
Observer 5 6.2 6.5 4.4 5.9
Observer 6 7.4 6.5 4.5 5.9
Observer 7 6.0 6.5 4.4 5.8
Observer 8 7.4 6.5 4.1 5.9
Observer 9 7.1 6.5 3.4 5.5
Observer 10 7.4 6.5 3.8 5.9
Observer 11 6.8 6.2 4.3 5.9
Observer 12 6.7 6.5 3.9 5.9
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A.3 Chapter 8
The maximum magnitude of the MDU (corresponding to potential coordinate system
failures) averaged over the patients in each volume category and the frequency of
occurrences as a percentage of total margin data points is presented in Table A.7. The
impact of these potential failures is assessed by comparing the interpolated structures
with the original structures using DSC (Table A.8).
Table A.7: Frequency and magnitude of maximum MDU for each patient.
Patient Polar (%) Spherical (%) Maximum MDU (mm)
1 3.10 0.81 17.91
2 0.00 0.00 19.13
3 1.76 0.05 21.80
4 52.45 44.33 17.07
5 0.04 0.00 13.88
6 0.02 0.00 21.43
7 9.38 0.54 27.78
8 2.41 0.11 20.89
9 0.10 0.06 13.73
11 0.60 0.10 15.14
12 3.31 1.88 13.65
13 0.00 0.00 11.74
14 0.03 0.12 21.13
15 0.05 0.02 14.04
16 0.00 0.00 15.04
17 3.42 5.84 10.43
18 1.64 1.33 14.03
19 0.48 0.19 10.59
20 0.21 0.07 12.51
21 0.39 0.09 19.71
22 0.15 0.00 18.69
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Table A.8: Average DSC for each patient of interpolated structures and original
structures.
Patient Polar Spherical
1 0.96 0.98
2 0.96 0.98
3 0.88 0.96
4 0.97 0.98
5 0.98 0.99
6 0.97 0.97
7 0.97 0.93
8 0.96 0.99
9 0.90 0.98
11 0.97 0.98
12 0.83 0.97
13 0.97 0.99
14 0.93 0.96
15 0.98 0.99
16 0.97 0.99
17 0.96 0.98
18 0.97 0.98
19 0.97 0.98
20 0.95 0.97
21 0.83 0.95
22 0.96 0.99
Table A.9: Significant differences in overlap assessed pairwise between polar (pol),
spherical (sph) and conventional (conv) margin approaches.
Target Volume Approaches Compared p value Z statistic
Small Conv > Pol <0.001 -8.53
Small Conv > Pol <0.001 -8.81
Small Pol > Sph <0.001 -4.02
GS Conv > Pol <0.001 -6.75
GS Sph > Pol <0.001 -5.19
Large Conv > Pol 0.03 -3.02
Large Sph > Conv <0.001 -6.68
Large Sph > Pol <0.001 -9.45
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Table A.10: Significant differences in potential MT assessed pairwise between polar
(pol), spherical (sph) and conventional (conv) margin approaches.
Target Volume Approaches Compared p value Z statistic
GS Pol > Conv <0.001 -3.58
GS Sph > Conv 0.001 -3.47
Large Pol > Conv <0.001 -3.92
Large Sph > Conv <0.001 -3.88
Large Pol > Sph 0.002 -3.06
Table A.11: Significant differences in definite MT assessed pairwise between polar
(pol), spherical (sph) and conventional (conv) margin approaches.
Target Volume Approaches Compared p value Z statistic
Small Pol > Conv <0.001 -3.81
Small Sph > Conv <0.001 -3.58
Large Conv > Sph <0.001 -3.66
Large Pol > Sph 0.001 -3.47
Table A.12: Significant differences in definite EIT assessed pairwise between polar
(pol), spherical (sph) and conventional (conv) margin approaches.
Target Volume Approaches Compared p value Z statistic
GS Sph > Conv 0.001 -3.32
GS Sph > Pol 0.011 -2.54
Large Conv > Pol 0.02 -2.28
Large Sph > Conv <0.001 -3.84
Large Sph > Pol <0.001 -3.88
